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A multicentre, randomised controlled trial of position
during the late stages of labour in nulliparous women
with an epidural: clinical effectiveness and an economic
evaluation (BUMPES)
Debra Bick,1 Annette Briley,2 Peter Brocklehurst,3* Pollyanna Hardy,4
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Mary Nolan,8 Oliver Rivero-Arias,4 Julia Sanders,5 Andrew Shennan9
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5School of Healthcare Sciences, Cardiff University, Cardiff, UK
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8Institute of Health and Society, University of Worcester, Worcester, UK
9Division of Women’s Health, King’s College London, London, UK
10School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
*Corresponding author p.brocklehurst@bham.ac.uk
Background: Epidural analgesia leads to increased risk of instrumental vaginal delivery (IVD). There is
debate about whether or not posture in second-stage labour influences the incidence of spontaneous
vaginal birth (SVB).
Objectives: In nulliparous women with epidural analgesia, does a policy of adopting an ‘upright position’
throughout second-stage labour increase the incidence of SVB compared with a policy of adopting a
‘lying-down’ position?
Design: Two-arm randomised controlled trial.
Setting: Maternity units in England and Wales.
Participants: Nulliparous women aged ≥ 16 years, at ≥ 37 weeks’ gestation with singleton cephalic
presentation and intended SVB, in second-stage labour with an epidural providing effective pain relief.
Interventions: (1) Upright position to maintain the pelvis in as vertical a plane as possible; and
(2) lying-down position to maintain the pelvis in as horizontal a plane as possible.
Main outcome measures: The primary outcome measure was incidence of SVB. Secondary outcomes
included augmentation, interventions to maintain blood pressure, duration of labour, episiotomy, genital
tract trauma, post-partum haemorrhage, maternal satisfaction, neonatal metabolic acidosis, 5-minute
Apgar score of < 4, resuscitation at birth and admission to neonatal unit. At 1 year for (1) women: urinary
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or faecal incontinence, dyspareunia and health-related quality of life; (2) for infants: major morbidity.
A cost–consequences analysis with a time horizon of 1 year after the birth from a NHS perspective.
Results: Between October 2010 and January 2014, 3236 women were randomised from 41 centres in
England and Wales. There was a statistically significant difference in the incidence of SVB between groups,
with 35.2% of women achieving a SVB in the upright group, compared with 41.1% in the lying-down group
(adjusted risk ratio 0.86, 95% confidence interval 0.78 to 0.94). There was no evidence of differences in most
of the secondary maternal or neonatal outcomes, or in long-term outcomes at the 12-month follow-up. No
significant overall cost differences were observed between upright and lying-down positions for mothers or
their babies.
Limitations: Measurement of adherence was challenging in this unmasked trial, and adherence could be
influenced by midwives’ beliefs about the allocated positions. If adherence was poor, this would have
diluted the difference between the two groups.
Conclusions: There is clear evidence of the benefit of adopting a lying-down position in second-stage
labour in nulliparous women with epidural analgesia, with no apparent disadvantages in either short- or
long-term outcomes for mother or baby, and this is cost neutral for the NHS.
Future work: Questions remain about whether or not other positions could increase the incidence of
SVB further in this group of women. The results also raise questions about the role of maternal position
in second-stage labour in women without an epidural.
Trial registration: Current Controlled Trials ISRCTN35706297.
Funding: This project was funded by the National Institute for Health Research Health Technology
Assessment programme and will be published in Health Technology Assessment, Vol 21, No. 65. See the
NIHR Journals Library website for further project information.
ABSTRACT
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Plain English summary
The BUMPES study aimed to find out whether or not women having their first babies who have an epiduraland give birth in an upright position (kneeling, sitting in a chair or upright in bed), rather than lying down
(on their side), are more likely to have a vaginal birth and less likely to need forceps or ventouse.
Between October 2010 and January 2014, 3236 women took part in the study at 41 maternity units in
England and Wales. Just over one-third (35.2%) of the women allocated to the ‘upright’ group had a
spontaneous vaginal birth, compared with 41.1% in the ‘lying-down’ group. Outcomes for the health of
the woman and baby (such as whether or not the baby needed special care or the woman had problems
with incontinence) were no different between the two groups, either in the short term (just after the birth)
or up to 1 year later.
The study offers clear evidence that women having their first baby and who have epidural pain relief in
labour are more likely to have a straightforward vaginal birth if they adopt a lying-down position in the
late stages of labour when their baby is ready to be born. There are no apparent disadvantages of lying
down for either the woman or her baby in the short or long term.
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Scientific summary
Background
As the most effective form of pain relief in labour, epidural analgesia is chosen by up to 30% of women in
the UK each year, and this proportion has remained relatively stable since 1990. Epidural analgesia leads to
an increased risk of instrumental vaginal delivery (IVD); however, this evidence comes mostly from trials using
epidural techniques that caused dense neuraxial blockade. ‘Low-dose epidurals’, which use low-dose local
anaesthetic in combination with opioids, result in a lower risk of IVD; however, using this method, the rate of
IVD is still higher than that in women with no epidural. Although low-dose epidurals preserve motor function,
allowing greater mobility throughout labour and enabling women to adopt upright positions, there is
debate about whether or not an upright posture in the second stage of labour increases the incidence of
spontaneous vaginal birth (SVB).
A Cochrane review of position in the second stage of labour in women without epidurals showed a reduction
in IVD in the upright group (Gupta JK, Hofmeyr GJ, Shehmar M. Position in the second stage of labour for
women without epidural anaesthesia. Cochrane Database Syst Rev 2012;5:CD002006). A Cochrane review of
position in the second stage of labour for women with epidural analgesia was published in 2013 (Kemp E,
Kingswood CJ, Kibuka M, Thornton JG. Position in the second stage of labour for women with epidural
anaesthesia. Cochrane Database Syst Rev 2013;1:CD008070), after the BUMPES trial was started. This
review included trials which compared upright with recumbent positions. The incidence of SVB reported in
the five included trials, comprising 879 women in total, was 1.02 [95% confidence interval (CI) 0.81 to
1.28]. The authors concluded that there was no clear evidence about whether or not position in the second
stage of labour made a difference to outcomes.
Objectives
To evaluate whether or not, in nulliparous women who choose low-dose epidural analgesia, a policy of
adopting an ‘upright position’ throughout the second stage of labour is associated with an increase in the
incidence of SVB compared with a policy of adopting a ‘lying-down’ position.
Design
A two-arm randomised controlled trial.
Setting
Maternity units in England and Wales.
Participants
Women admitted to a participating labour ward who fulfilled all of the following criteria were eligible to
be recruited and randomised into the trial:
l aged ≥ 16 years
l ≥ 37 weeks’ gestation
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l nulliparous (no previous delivery ≥ 24+0 weeks’ gestation)
l singleton cephalic presentation
l intended SVB
l in the second stage of labour
l with a low-dose epidural in situ during the first stage of labour, providing effective pain relief
l able to understand printed documentation produced in English
l able to give written answers in English.
Exclusion criteria
Women who did not fulfil all of the inclusion criteria were not included in the study.
Interventions
Women were allocated to a policy of (1) an upright maternal position that would maintain the pelvis in as
vertical a plane as possible during the second stage of labour, with the intention of continuing this until
the birth (this could include walking, standing, sitting out of bed, supported kneeling or completely upright
in an obstetric bed for as much of the second stage as possible); or (2) a lying-down maternal position
(left or right lateral, to prevent aortocaval compression), which would maintain the pelvis in as horizontal a
plane as possible during the second stage of labour, with the intention of continuing this until the birth.
Randomisation
Participants were randomised to the allocated intervention (allocation ratio 1 : 1) using a secure web-based
central randomisation service. No stratification by clinical characteristics was undertaken, although there
was stratification by centre.
Main outcome measures
Primary outcome measure
The primary outcome measure was the incidence of SVB.
Secondary short-term outcomes
l Instrumental vaginal delivery (forceps and ventouse).
l Caesarean section.
l Augmentation of labour.
l Major interventions to maintain blood pressure (e.g. vasopressors).
l Hypotension (systolic blood pressure of < 100 mmHg prior to delivery).
l Application of fetal scalp electrode.
l Fetal blood sampling.
l Total doses of epidural local anaesthetic and opioids administered after randomisation.
l Duration of active second stage of labour.
l Total duration of second stage of labour.
l Additional anaesthesia used for operative delivery.
l Active management of the third stage of labour.
l Episiotomy.
l Pain during delivery.
l Genital tract trauma (location and severity).
l Manual removal of the placenta.
l Primary post-partum haemorrhage necessitating blood transfusion.
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l Duration of maternal inpatient stay after delivery.
l Satisfaction with experience of birth.
l Cord artery pH of < 7.05 in the second stage of labour (this is 2 standard deviations below the mean)
with base deficit of ≥ 12 mmol/l (this is the threshold above which the risks of neurological
damage increase).
l Presence of meconium-stained liquor.
l Apgar score of < 4 at 5 minutes.
l Resuscitation at birth.
l Skin-to-skin contact within the first hour of birth.
l Initiation of breastfeeding within the first hour of birth.
l Duration of infant inpatient stay.
l Admission to neonatal unit and duration of stay.
At 1 year
l Urinary incontinence.
l Faecal incontinence.
l Other bowel problems.
l Dyspareunia.
l General physical and psychological health.
l Major infant morbidity, for example gross neurodevelopmental delay, including cerebral palsy
(if a diagnosis has been made).
l Hospital admissions.
Economic evaluation
A cost–consequences analysis with a time horizon of a 1-year follow-up and a NHS perspective was
conducted alongside BUMPES.
Data collection schedule
Information at trial entry was collected from hospital notes and entered onto specifically designed study
data collection booklets. The attending midwife recorded data about what position the woman was in
during the second stage of labour ‘for the majority of the time in the last 15 minutes’, if this position had
changed from the allocated position and the reasons for this. We collected clinical outcome information on
the birth as well as neonatal outcomes and hospital inpatient stay data. As soon as possible after the birth,
the woman was asked to complete a one-page questionnaire asking about her satisfaction with her
birth experience. Women with surviving infants were followed up at 1 year with a self-administered
questionnaire asking about specific health problems, their general health, the well-being of their infant’s
health and their use of NHS health-care resources.
Sample size and analysis
Assuming a rate for the primary outcome of SVB of 55% in the control group [derived from data
published from the Comparative Obstetric Mobile Epidural Trial (COMET), which was a randomised trial
that compared conventional epidural analgesia with low-dose epidural analgesia in nulliparous women in
labour], a sample size of 3000 women (1500 in each arm) would have 90% power to detect a clinically
significant (absolute) difference of 6% in the SVB rate between the two policies (with 95% CIs).
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A detailed statistical analysis plan was developed and approved by the Trial Steering Committee prior to
analysis of the trial data. For the primary analysis, participants were analysed in the groups into which they
were randomly allocated, regardless of position recorded at any time during the second stage of labour.
In order to take account of the number of comparisons, 95% CIs are presented for the primary outcome
and 99% CIs for all other outcomes.
To examine whether or not the effect of the policy of position during the second stage of labour was
consistent across specific subgroups, the following prespecified subgroup analyses were undertaken:
l gestational age (37+0 to 38+6 weeks; 39+0 to 40+6 weeks; and ≥ 41+0 weeks)
l maternal age (≤ 24 years, 25–29 years, 30–34 years and ≥ 35 years)
l augmentation with oxytocin (Syntocinon®; Novartis Pharmaceuticals UK Ltd, Frimley/Camberley, UK)
in the first stage of labour (yes/no)
l Index of Multiple Deprivation (population-based quintiles 1–5).
Results
Between October 2010 and January 2014, 3236 women were randomised to the BUMPES trial from
41 participating centres in England and Wales.
A total of 143 women (4.4%) were excluded from the analysis of the primary outcome. Data collection
booklets were available for 100% of women recruited and analysed. Follow-up at 1 year was achieved for
61% of women.
Baseline characteristics were similar between the two arms of the trial.
There was a clear difference in the incidence of the primary outcome, SVB, between the groups, with
35.2% of women achieving SVB in the upright group, compared with 41.1% in the lying-down group
(adjusted relative risk 0.86, 95% CI 0.78 to 0.94). This represents a 5.9% absolute risk increase in the
chance of SVB in the lying-down group.
There was no evidence of a difference in most of the secondary maternal outcomes after study entry and
during the second stage of labour. There was a significant difference in the duration of the active second
stage of labour, which was shorter in the lying-down group (geometric mean ratio 1.08 minutes, 99% CI
1.01 to 1.15 minutes). Other secondary maternal outcomes, such as IVD and caesarean section, suggested
an increased risk associated with the upright position, but these differences were not statistically significant
at the 1% level. For example, the incidence of episiotomy was higher in the upright group than in the
lying-down group (although the difference was not significant at the 1% level). There were no statistically
significant differences in the risk of perineal trauma, although there appeared to be a slightly higher
incidence of obstetric anal sphincter injury in the upright group (6.7%) than in the lying-down group (5.3%),
but again this difference was not statistically significant at the 1% level.
Maternal satisfaction in labour was similar between the two groups.
Infant outcomes were extremely good throughout, with very few babies having a low Apgar score at
5 minutes or evidence of metabolic acidosis. Overall, about 12% of babies required resuscitation at birth.
The prespecified subgroup analyses showed no evidence of heterogeneity between any of the
prespecified subgroups for the primary outcome of SVB.
There was no evidence of any differences between the groups in relation to the incidence or severity
of urinary incontinence, faecal incontinence, constipation, haemorrhoids or dyspareunia, or general
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well-being. Similarly, there was no evidence of a difference in the incidence of diagnosed cerebral palsy or
severe neurodevelopmental delay in any of the infants at 1 year.
Cost-effectiveness analysis
Women randomised to the lying-down position consumed significantly fewer NHS resources than those
randomised to an upright position during the original hospital stay [mean cost difference of £59 (95% CI
£6 to £111) favouring the lying-down position]. This result was driven by more SVBs in the lying-down
arm. At the 12-month follow-up, there were no significant differences in the overall costs incurred by
mothers or their babies between the upright and lying-down groups. The significantly higher costs incurred
by the women in the upright group were offset by the slightly, but non-significantly, higher costs incurred
during follow-up by the women in the lying-down group.
Conclusions
There is clear evidence of a benefit of adopting a lying-down (lateral) position in the second stage of
labour in nulliparous women with epidural analgesia, with no apparent disadvantages in relation to either
short- or long-term outcomes for either mother or baby, and this is cost neutral for the NHS.
Like all pragmatic trials, the study had limitations. With an intervention such as this, masking is impossible,
so the results may have been influenced by the women’s and the midwives’ perceptions of the different
positions in their ability to achieve a SVB. Given that existing National Institute for Health and Care
Excellence guidance recommends that women with an epidural should be encouraged to adopt whatever
upright position they find comfortable, we might expect the trial results to suggest an improvement in SVB
with an upright position if midwives’ and women’s behaviour was altered in these positions because of a
firm belief that these were preferable. The findings that the lying-down position increased the chances of
achieving a SVB suggest that this potential bias was either absent or minimal in its impact, or that the
likelihood of the lying-down position leading to a SVB may be even greater.
We can only speculate about the mechanism by which a lying-down position increases the chance of a
SVB. We have no direct measurements of the density of the epidural block in the two positions or of the
level of the block. It is possible that women in the upright position acquired a more dense block around
the birth canal because of the effect of gravity on the epidural drugs, which could have made expulsive
efforts more difficult; however, the similarity of drug doses used in each group would suggest that this is
unlikely. Women in the upright group, who may have been sitting, may have restricted the pelvic outlet
because of the position on the coccyx or because of lower genital tract oedema and venous obstruction
causing swelling of the soft tissues obstructing the pelvic outlet. In addition, it is possible that, in the
lying-down group, easing of pressure of the fetal head on the pelvis improved uterine blood flow and
therefore improved uterine activity. This would suggest a difference in the risk of operative delivery
associated with failure to progress; however, the distribution of indications for operative delivery appeared
to be the same in both groups. In addition, there was little difference in the use of oxytocin because of
delay in labour progress after trial entry.
The response rate to the 1-year follow-up was 61%. Therefore, there is a possibility that the follow-up
results are less than robust because of non-response bias. There were, however, no apparent differences in
the response rates or characteristics of the two randomised groups, suggesting that there were minimal
biases in the comparison of the two groups.
The lack of an impact of the risk of SVB on longer-term outcomes such as faecal incontinence is of
interest. The observation that IVD is associated with increased risks of faecal incontinence is robust;
however, in the BUMPES trial, the differences between the randomised groups of women in their risk of
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SVB and IVD were relatively small, so, although there are associations between different modes of birth
and long-term outcomes, these are likely to be diluted in a trial in which the differences in actual mode of
birth are relatively modest (a 6% absolute difference in the risk of SVB). This is likely to explain the lack
of an observed difference in long-term outcomes.
Trial registration
This trial is registered as ISRCTN35706297.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Scientific background
As the most effective form of pain relief in labour, epidural analgesia is chosen by up to 30% of women in
the UK each year,1 and this proportion has remained relatively stable over the last decade.2 The uptake is
greater in nulliparous women, with up to 40% of women having an epidural in large obstetric sites.3
However, a systematic review of 23 randomised controlled trials (RCTs) that compared epidural analgesia
with non-regional or no analgesia in labour found that epidural analgesia was associated with an
increased risk of instrumental vaginal delivery (IVD) [risk ratio (RR) 1.42, 95% confidence interval (CI) 1.28
to 1.57].4
The trials that made the most contribution to the evidence base were conducted with epidural techniques
that caused dense neuraxial blockade. Significant peripheral motor blockade, which can accompany
conventional high-dose local anaesthetic epidural analgesia, inhibits mobility or the adoption of upright
positions in labour. ‘Low-dose epidurals’, which use low-dose local anaesthetic in combination with opioids
(usually fentanyl), were introduced in the early 1990s and are now in widespread use in the UK. This
approach has been shown to result in a lower risk of IVD;5 however, the rate of IVD is still higher than that
in women with no epidural.6
Reducing the rate of IVD and increasing the spontaneous vaginal birth (SVB) rate would reduce short- and
long-term morbidity for women by reducing the risk of perineal trauma and the effects of surgical repair.
The incidence of perineal pain, dyspareunia and incontinence following IVD could also be reduced.7–12
Although mobile epidurals preserve motor function (allowing greater mobility throughout labour) and can
enable women to adopt upright positions, there is debate about whether or not an upright posture in the
second stage of labour increases the SVB rate.
It is worth noting that the terms ‘ambulation’ and ‘mobilisation’ are often used interchangeably in the
literature about epidural techniques that maintain motor function in the lower limbs. As the posture a
woman adopts in labour is in part dependent on the motor power she retains, and this can be compromised
by the peripheral motor blockade that accompanies effective epidural pain relief, it is clearly important to
draw a distinction between mobilisation, the ability to move one’s legs, change position or move around the
bed normally, and ambulation, which refers to the act of walking during labour. The ability to adopt upright
postures in labour requires that women retain the capacity to mobilise, and some of these women will be
able to ambulate.
A systematic review of the impact on mode of delivery of ambulation or upright positions in the first stage
of labour (before full dilatation of the cervix) among women with epidurals found no significant difference
between IVD (RR 1.16, 95% CI 0.93 to 1.44) and caesarean section (RR 0.91, 95% CI 0.70 to 1.19).13 The
second stage of labour may represent a period during which the adoption of an upright posture could
exert the greatest influence and affect delivery mode by facilitating descent of the fetal head. A Cochrane
review of position in the second stage of labour in women without epidurals found a reduction in IVD rate
in the upright group (19 trials; RR 0.78, 95% CI 0.68 to 0.90).14
Effectiveness of an upright position in the second stage of labour for
women with epidurals
A Cochrane review of position in the second stage of labour among women with epidural analgesia was
published in 2013,15 after the BUMPES trial started. This review included trials that compared upright
DOI: 10.3310/hta21650 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 65
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Bick et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
1
positions with recumbent positions. The RR of SVB reported in the five included trials, including 879 women,
was 1.02 (95% CI 0.81 to 1.28). There was clinical heterogeneity between the trials in relation to the
eligibility criteria (some included multiparous women whereas others were restricted to nulliparous women)
and in the nature of the interventions. In the upright group, for example, some women were actively
encouraged to walk, and others were supported in a sitting position. In the recumbent group, some trials
had allocated women to a sitting position and others to a lateral position. The authors concluded that
there was no clear evidence about whether or not position in the second stage of labour made a difference
to outcomes.15
Effects on short- and longer-term maternal morbidity
An intervention that increases the rate of SVB by reducing the rate of IVD or caesarean section would also
be expected to have an effect on short- and longer-term maternal morbidity. Faecal incontinence is clearly
documented as being associated with forceps,11,16 including ongoing symptoms in women who only ever
have one forceps delivery.17 There may also be an increased risk of urinary incontinence, although this
may be more closely associated with a longer second stage of labour;18,19 however, women who have a
caesarean section have a lower risk of symptoms.20,21 Other bowel problems such as haemorrhoids19,22,23
and constipation24 are more common after IVD, as are perineal pain and dyspareunia.24,25 Caesarean
section has many adverse sequelae, but, with the exception of faecal incontinence, most of these
symptoms are less likely to occur in association with this delivery mode. It is therefore important to
investigate positive impacts as well as any possible negative impacts of upright positions in the second
stage of labour on maternal health outcomes.
There is increasing interest in obtaining maternity service users’ views of satisfaction with their experience
of birth, as an indicator of the quality of their care and to inform organisational and policy changes.26
Satisfaction is poorly defined and measured, although it is generally agreed that it is a multidimensional
concept.27,28 In a systematic review of factors influencing women’s satisfaction with birth, with a focus on
the role of pain and pain relief, four factors (caregiver support, participation in decision-making, personal
expectations and caregiver–patient relationship) were identified as important influences.28 As position
in the second stage of labour could influence a woman’s perceptions of the support she receives, her
feelings of control and her expectations and experiences of labour and birth, satisfaction is an important
consideration. The impact of negative consequences of the position adopted in the second stage of labour
on these perspectives should also be identified.
Policy and practice at the time the trial commenced
Up to 30% of women in the UK use epidural analgesia for pain relief at some point in labour,1 with wide
variation in the rate of epidural use between units. In a 1997 survey of UK units regarding epidural analgesia
for labour, the epidural rate, including ‘low-dose’ epidurals, ranged from 0% to 85%, with an average rate
of 24%. Of the 190 units that replied to the survey, 45 (24%) offered ‘low-dose epidurals’.29 There is
variation in the epidural technique employed to provide pain relief in labour and hospital policies governing
maternal ambulation with an epidural in situ. A UK survey was conducted via the Obstetric Anaesthetists’
Association in 2008 to characterise national epidural practice and policy, with a response rate from lead
clinicians of 80%.30 It found that 95% of respondent units employed various epidural techniques consistent
with the adoption of a range of upright positions, including ambulation, and that less than 50% of women
actually did ambulate. Findings from the BUMPES trial are therefore widely generalisable to the majority of
the nulliparous population that chooses epidural pain relief. With regard to reported hospital policies, 34%
permitted maternal ambulation with low-dose epidural analgesia in situ.30 Of those units that did not permit
ambulation, 37% cited lack of evidence of a beneficial effect as a reason for this policy. This reluctance may
reflect the current uncertainty in this field and that in general midwives have less experience of enabling
women with epidurals to ambulate in second-stage labour rather than being in bed.
INTRODUCTION
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Rationale for a trial comparing upright with lying-down position
The National Institute for Health and Care Excellence (NICE) guidelines on intrapartum care published in 200731
(with no change in the update published in 2014) noted that there is ‘no effect of mobilisation following
epidural analgesia on any maternal or neonatal outcomes’, and recommended that ‘women with regional
analgesia should be encouraged to move and adopt whatever upright positions they find comfortable
throughout labour’ (section 1.5.7, p. 22). This guidance is likely to lead to an increase in the use of upright
positions, hence the need to compare upright positions with ‘lying-down’ positions rather than with usual care,
given that usual care will increasingly include women assuming an upright position. Good-quality evidence is
needed on whether or not upright positions in the second stage of labour in women with epidural analgesia
have any beneficial effect on delivery mode and other important outcomes. It is crucial that the policies for the
upright and comparison groups are clearly defined and monitored to ensure separation of the two approaches
and to provide robust evidence about whether or not adopting an upright position does improve outcomes for
women and their babies.
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Chapter 2 Methods
Aim of the BUMPES trial
This was a multicentre RCT in which the primary objective was to evaluate whether or not, in nulliparous
women who choose low-dose epidural analgesia, a policy of adopting an upright position throughout the
second stage of labour is associated with an increase in the incidence of SVB, compared with a policy of
adopting a lying-down position.
This objective was supported and supplemented by the following secondary objectives:
l to evaluate whether or not there are differences between the two policies in important clinical
outcomes for women and babies around the time of birth and 1 year post partum
l to evaluate the cost-effectiveness of the two policies for position during second-stage labour from a
NHS perspective
l to measure women’s satisfaction with, and experience of, labour and delivery.
Trial design
The BUMPES study was a pragmatic, multicentre, individually randomised controlled trial that had a
target recruitment of 3000 nulliparous women who had a low-dose epidural in situ. It was a two-arm
parallel-group trial with one arm allocated to adopting an upright position during the second stage of
labour and one arm allocated to adopting a lying-down position during the second stage of labour
(Figure 1).
Participant eligibility
The following inclusion criteria were applied throughout participant recruitment.
Inclusion criteria
Women admitted to a participating labour ward who fulfilled all of the following criteria were eligible to
be randomised into the trial:
l aged ≥ 16 years of age
l ≥ 37 weeks’ gestation
l nulliparous (no previous delivery ≥ 24+0 weeks’ gestation)
l singleton cephalic presentation
l intended SVB
l in the second stage of labour
l with a low-dose epidural in situ during the first stage of labour, providing effective pain relief
l able to understand printed documentation produced in English
l able to give written answers in English.
Exclusion criteria
Women who did not fulfil all of the inclusion criteria were not included in the study.
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Sample population
All women who met the inclusion criteria were considered potentially eligible to participate in the study.
Study setting
Trial recruitment was undertaken in the labour wards of participating NHS maternity hospitals.
Information for women and obtaining informed consent
Information about the trial was provided to all nulliparous women during the antenatal period, after their
booking appointment. This process was individualised for each participating centre depending on their
routine practice to maximise the number of women offered information well in advance of labour. For
example, in some sites, women were provided with information about the trial at their routine anomaly
scan appointment (18–22 weeks). All women had the opportunity to ask questions of their midwives or
obstetricians at the hospital, or they could contact the trial office. When a woman in a participating centre
had an effective epidural established during the first stage of labour, she could then be offered a participant
Information offered to all pregnant nulliparous women
Participant information leaflet provided: 
nulliparous women aged > 16 years, at > 37 weeks’ gestation 
who have a singleton cephalic presentation and intend a 
SVB, in labour with an epidural sited
Consent
Enter second-stage labour, eligible
Randomisation
Data collection 
1 year after birth 
(1-year follow-up questionnaire to be
completed by woman)
• Data collection in labour (data 
   collection booklet completed by 
   midwife)
• Data collection prior to postnatal
   discharge (maternal satisfaction 
   questionnaire completed by woman)
Lying-down positionUpright position
FIGURE 1 Flow chart of participant recruitment.
METHODS
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information leaflet on the study. If, after reading this and having the opportunity to ask questions, she was
willing to take part in the study, then informed consent was taken. The participant information made it
clear that women were free to withdraw from the trial at any time for any reason without prejudice to their
future care, and with no obligation to a give a reason for the withdrawal. Written informed consent was
obtained by a health professional (e.g. midwife, obstetrician or anaesthetist) with delegated authority from
the principal investigator at each site. Consent comprised a dated signature from the woman and a dated
signature of the person who obtained informed consent. A copy of the signed informed consent document
was given to the woman. In addition, one copy was retained in the woman’s medical notes, one was
retained in the study site file and one was sent to the Trial Co-ordinating Centre.
Interventions
Women were allocated to a policy of either upright maternal position (intervention group) or lying-down
maternal position (control group).
Intervention group
Women were allocated to a policy of upright maternal position that would maintain the pelvis in as vertical
a plane as possible during the second stage of labour, with the intention of continuing this until the birth.
Women allocated to the ‘upright’ group were encouraged by their midwife to adopt positions that allowed
for as upright a posture as possible. This could include walking, standing, sitting out of bed, supported
kneeling or completely upright in an obstetric bed (Figure 2) for as much of the second stage as possible.
(a) (b)
(c) (d)
FIGURE 2 Possible positions for women randomised to the upright maternal position. (a) Seated; (b) supported
kneeling; (c) seated with extended legs; and (d) completely upright.
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Control group
Women were allocated to a policy of a lying-down maternal position that would maintain the pelvis in as
horizontal a plane as possible during the second stage of labour, with the intention of continuing this until
the birth. Women allocated to the ‘lying-down’ group were encouraged to adopt a lying-down position
that would mean lateral positions or lying down in bed for as much of the second stage of labour as
possible. The bed could be tilted at up to a maximum of 30 degrees from horizontal (Figure 3).
Monitoring of adherence to allocation
In the second stage of labour, women with an effective epidural anaesthetic frequently have no desire to
push. After confirmation of the second stage of labour, women were entered into the study. Midwives
were encouraged to manage the second stage in two phases: a period of passive second-stage labour,
allowing time for descent of the fetal head, followed by an active phase of expulsive pushing.
Training emphasised to the midwives the importance of supporting the woman in her allocated position,
especially for the passive stage (which could last up to 2 hours). Positions were recorded on the trial
worksheet at 15-minute intervals using a tick box, and midwives recorded ‘reason for change’ if the
woman was moved out of her allocated position. As a pragmatic study, it was agreed that there would
be expected reasons for changing position, for example fetal distress, fetal blood sampling or maternal
discomfort, or to help improve pushing in the active second stage of labour. It was emphasised that
midwives were required to record this information.
Randomisation
Participants were randomised to the allocated intervention (allocation ratio 1 : 1) using a web-based central
service. To confirm eligibility, investigators were required to confirm the woman’s age and gestational age,
that this was the woman’s first birth, that the fetus was a singleton with cephalic presentation and that
an effective epidural was in situ, as well as obtaining signed consent. The randomisation software used
random permuted blocks of sizes 2, 4, 6, 8 and 10, selected according to the proportions specified by
Pascal’s triangle (1 : 4 : 6 : 8 : 10) to ensure that the staff recruiting women to the trial could not reliably
predict the next allocation. Because of the large numbers of women recruited in each centre, no stratification
by clinical characteristics was planned, although there was stratification by centre. The procedures for
(a)
(b)
FIGURE 3 Possible positions for women randomised to the lying-down maternal position. (a) From in front; and
(b) from behind. Note: a truly supine position (i.e. flat on the back) should not be used during labour because of
the risk of aortocaval compression from the gravid uterus causing maternal hypotension.
METHODS
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randomisation were fully documented, tested prior to the start of the trial, and monitored by the
randomisation centre during the trial.
Outcome measures
Primary outcome measure
The primary outcome measure was the incidence of SVB.
Secondary outcomes
The following secondary outcomes were collected.
Mode of delivery
l Instrumental delivery (forceps and ventouse)
¢ and primary indication.
l Caesarean section
¢ and primary indication.
Outcomes from randomisation until delivery
l Augmentation of labour.
l Major interventions to maintain blood pressure (e.g. vasopressors).
l Hypotension (systolic blood pressure of < 100 mmHg prior to delivery).
l Application of fetal scalp electrode.
l Fetal blood sampling.
l Total doses of epidural local anaesthetic and opioids administered after randomisation.
l Duration of active second stage of labour.
l Total duration of second stage of labour.
l Additional anaesthesia used for operative delivery.
Immediate post-delivery outcomes
l Active management of the third stage of labour.
l Episiotomy.
l Pain during delivery.
l Genital tract trauma (location and severity).
l Manual removal of the placenta.
l Primary post-partum haemorrhage requiring blood transfusion.
Postnatal period: woman
l Duration of inpatient stay after delivery.
l Satisfaction with experience of birth.
Postnatal period: infant
l Cord artery pH of < 7.05 in second stage of labour [this is 2 standard deviations (SDs) below the mean]
with a base deficit of ≥ 12 mmol/l (this is the threshold above which the risks of neurological
damage increase).
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l Presence of meconium-stained liquor.
l Apgar score of < 4 at 5 minutes.
l Resuscitation at birth.
l Skin-to-skin contact within the first hour of birth.
l Initiation of breastfeeding within the first hour of birth.
l Duration of inpatient stay.
l Admission to neonatal unit and duration of stay.
One year after birth: woman
l Urinary incontinence.
l Faecal incontinence.
l Other bowel problems.
l Dyspareunia.
l General physical and psychological health.
One year after birth: infant
l Major morbidity, for example gross neurodevelopmental delay, including cerebral palsy (if a diagnosis
has been made).
l Hospital admissions.
Data collection schedule
Information at trial entry, including eligibility and maternal characteristics, was collected from hospital
notes onto the specifically designed data collection booklet (DCB) (see Appendix 1). The position to which
the woman was allocated was recorded on the DCB in two places – once in the eligibility section and
again on the worksheet used to record the woman’s actual positions. As soon as possible after the woman
was randomised, the attending midwife encouraged her into the allocated position and started recording
on the DCB what position the woman was in ‘for the majority of the time in the last 15 minutes’, and if
this position had changed from the allocated position and, if so, the reasons for this. Information on drugs
taken after study entry and during labour was also recorded, as was other clinical information about the
labour. The DCB also allowed for the collection of clinical outcome information on the delivery, as well as
on neonatal outcomes and hospital stay.
If either the woman or the infant received a higher level of care (HLC), the relevant HLC form (see
Appendices 2 and 3) was completed by the attending midwife.
As soon as possible after delivery, the woman was asked to complete a one-page questionnaire asking
about her satisfaction with her birth experience, as well as asking her to provide an overview of what
position she was in most of the time after study entry (see Appendix 4).
Women with surviving infants were followed up at 1 year with a self-administered questionnaire asking
about their general health and well-being, with specific questions relating to any urinary and bowel
problems. This questionnaire also requested information on the use of health services for themselves or
their child (see Appendix 5). Prior to contact, mortality status and place of residence of both the woman
and her infant were checked using NHS summary care records. Only women whose infants resided at the
same address were contacted.
An overview of the time points at which trial data were collected is presented in Table 1.
METHODS
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Sample size
The proposed sample size was 3000 women. At the time of writing the funding application, the assumed
rate of the primary outcome of SVB in the control group was 55%. This was derived from data published
from the Comparative Obstetric Mobile Epidural Trial (COMET) reflecting SVB rates in nulliparous women
with a mobile epidural in the second stage of labour.5 A total sample size of 3000 women (1500 in each arm)
would have 90% power to detect a clinically significant (absolute) difference of 6% in the SVB rate between
the two policies (with a 95% CI). The cost of implementing this technology is low; therefore, even modest
differences in outcome are likely to be cost-effective. Detecting the smallest and most clinically relevant effect
size possible was therefore desirable. A 6% absolute risk difference, which equates to a 10% RR reduction
(approximately), was well within the uncertainty of the existing evidence (despite the existing trials’
heterogeneity) and was considered sufficient to change clinical practice.
The proportion of the upright group achieving a SVB was anticipated to be 61% under the null hypothesis.
The test statistic used was the two-sided z-test with pooled variance. The significance level of the two-sided
test was targeted at 5%. When considering longer-term outcomes, the proposed sample size of 3000 would
be sufficient to detect a difference in the prevalence of faecal incontinence of 12% in the control group
compared with 8% in the intervention group. The incidence of this outcome has been estimated as 14%
among forceps deliveries and 10% among women with a SVB.11
On collation of the pilot data for an interim analysis presented to the Data Monitoring Committee (DMC)
in 2011, it was recognised that the combined primary outcome event rate was lower than anticipated.
As of 6 December 2011, the overall SVB rate for BUMPES (combining upright and lying-down groups) was
33.8% [(95% CI 26.1% to 42.1%) based on 49/145 events]. With a reduction in the control group event
rate (from an anticipated 55% to between 30% and 40%), keeping the sample size fixed at 3000 would
mean that a RR of between 1.13 and 1.19 would be detectable, equivalent to an absolute risk reduction
of 5–6%. Although there was not sufficient power to detect a RR as small as the planned 1.11, the
TABLE 1 Summary of data collection schedule
Data collection
instrument
Time point
Person completing the data collection instrument
During
labour
After
delivery 12 months
Woman and infant
DCB
✗ ✗ Completed by the attending midwife during labour and
immediately after birth
For all participating women and infants
HLC form: woman ✗ Completed by the attending midwife during the woman’s
admission and/or immediately after discharge from
hospital; checked by the local principal investigator
Only completed for women receiving a HLC following
delivery
HLC form: infant ✗ Completed by the attending midwife during the infant’s
admission and/or immediately after discharge from
hospital; checked by the local principal investigator
Only completed for infants receiving a HLC following birth
Maternal satisfaction
form
✗ Completed by the woman as soon as possible after
delivery
For all participating women
Follow-up
questionnaire
✗ Postal questionnaire completed by the woman
For all women whose babies were alive and both the
woman and baby were resident at the same address
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absolute risk detectable is similar. The Trial Steering Committee (TSC) agreed that changes to the target
sample size were therefore unnecessary.
Governance
Ethics arrangements
Favourable ethics approval for the study was granted by the National Research Ethics Service – Oxfordshire
Research Ethics Committee (REC) B on 5 January 2010 (reference number 09/H0605/114). Approval was
also sought from the Health and Social Care Information Centre (now known as NHS Digital) to establish
the status of the mothers and their babies and details of the general practice at which they were registered.
This was to ensure that 1-year follow-up questionnaires were not sent if either mother or baby may have
died or if the family had changed address. NHS Digital approval was granted on 29 January 2013.
Approval was obtained from the research and development (R&D) departments for all participating hospitals.
Table 2 provides details of the substantial amendments to the protocol approved by the REC. The R&D office
of each participating hospital was notified of all amendments after REC approval was received. The REC were
notified of all serious adverse events (SAEs) and progress reports were submitted annually.
The trial was registered with the International Standard Randomised Controlled Trial Register under the
reference number 35706297, and was adopted into the National Institute for Health Research (NIHR)
portfolio under reference 8375.
TABLE 2 Research Ethics Committee amendments
Amendment Date
Description of main items in the request for approval (including
version of protocol if revised)
Substantial
amendment 1
9 June 2010 Protocol version 2 (1 March 2010)
Key changes to the protocol were clarification on defining the term
‘nulliparous’, rewording the data collection section and updating the
photographs of maternal positions. The PIL, consent form and antenatal
leaflet were also updated
Substantial
amendment 2
13 August 2010 Submission of the maternal satisfaction questionnaire for approval
Non-substantial
amendment 1
4 August 2010 Administrative updates to the version numbers on the PIL and consent
forms
Non-substantial
amendment 2
23 September 2010 Administrative update to the antenatal leaflet
Substantial
amendment 3
7 March 2011 Protocol version 3 (1 December 2010)
The majority of changes to the protocol were typographical or were made
to increase clarity. The term ‘mobile epidural’ was replaced by ‘low-dose
epidural’ throughout the document for consistency and to conform with
clinical terminology. The secondary outcomes: ‘application of fetal scalp
clip’ and ‘fetal blood sampling’ were added in order to assess concern over
potential fetal distress
Recruitment posters were also designed to encourage midwives to recruit
women to BUMPES
Substantial
amendment 4
25 July 2011 Protocol version 4 (20 July 2011)
Transfer of study sponsorship from the NPEU, University of Oxford to UCL.
All study documents updated to reflect changes. The follow-up
questionnaire entitled ‘You and Your First Child’s Health at One Year’ and
a study poster were also submitted for approval
METHODS
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TABLE 2 Research Ethics Committee amendments (continued )
Amendment Date
Description of main items in the request for approval (including
version of protocol if revised)
Substantial
amendment 5
24 November 2011 With study sponsorship and co-ordination being transferred from the NPEU
to UCL, a letter was designed that notified women of the intention to also
transfer their data (including name and address details) to UCL
Non-substantial
amendment 3
14 February 2012 Contact details updated on the study protocol, PIL, consent form,
1-year follow-up form, maternal satisfaction form and antenatal leaflet
Non-substantial
amendment 4
13 March 2012 Updated version number of PIL referenced in consent form
Substantial
amendment 6
2 May 2012 Protocol version 5 (2 March 2012)
Protocol changes made to reflect the change in contact details of
the co-ordinating team, number of participating centres and minor
typographical changes. For women with missing consent forms,
a re-consent form and a covering letter for this form were also submitted
for approval. The photos of the ‘lying-down’ positions were changed in
the PIL and antenatal leaflet to reflect the positions more accurately.
A life-size poster to be placed in the antenatal clinics and delivery suites
was also submitted for approval
Substantial
amendment 7
12 September 2012 A follow-up reminder letter was designed to be sent to recruited women
when no response was received following a 1-year follow-up questionnaire
being sent out
Substantial
amendment 8
7 January 2013 Change of principal investigator at one of the participating centres.
Minor amendment raised as substantial in error
Substantial
amendment 9
16 April 2013 The 1-year follow-up accompanying letter was designed to be sent with
1-year follow-up questionnaire. As the questionnaire sent out coincided
with the infant’s first birthday, a gender-neutral birthday card was
designed and submitted for approval. Minor changes were also made to
the re-consent letter
Non-substantial
amendment 5
16 May 2013 Permission to use NIHR ‘OK to Ask’ promotion with the addition of the
BUMPES logo and the words ‘Ask your midwife about’. This was used to
promote BUMPES locally for International Clinical Trials Day (20 May 2012)
Substantial
amendment 10
21 February 2014 The 1-year follow-up accompanying letter content and layout were
updated to include details of the online questionnaire. Approval was
sought to remind participants to complete questionnaires via text message
and/or e-mail. Details regarding a small incentive to complete the 1-year
follow-up questionnaire in the form of a £5 shopping voucher were also
included in the letter, e-mail and text message sent to women
Substantial
amendment 11
14 July 2014 Submission of the nested study protocol to assess the effectiveness on
the return rate of the 1-year follow-up postal questionnaires. This was a
promise of a monetary incentive (£10 voucher) made at the point of
sending the initial follow-up questionnaire or on reminder letters only.
One-year follow-up accompanying letters were also updated to include
details on incentives
Substantial
amendment 12
27 April 2015 Protocol version 6 (27 April 2015)
Changes on how adherence to the allocated position would be analysed,
minor clarification to the per diem cost calculation and clarification on how
the study data would be analysed
NIHR, National Institute for Health Research; NPEU, National Perinatal Epidemiology Unit; PIL, participant information leaflet;
UCL, University College London.
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Trial governance
Trial Steering Committee
The TSC included an independent chairperson, four other independent professional members (statistician,
consultant anaesthetist, health economist, professor of midwifery) and one patient representative. Non-
independent members included the chief investigator. Membership of the committee was approved by the
NIHR Health Technology Assessment (HTA) programme. The TSC agreed a charter at its first meeting,
based on that used by the Medical Research Council Clinical Trials Unit. The TSC met five times.
Data Monitoring Committee
The DMC was established for the trial and met as and when the DMC members requested.32 The DMC
comprised an independent chairperson and three independent members (a statistician, a professor of
women’s health and a consultant in maternal and fetal medicine). Membership of the committee was
approved by the NIHR HTA programme. During the period of recruitment to the trial, interim analyses were
supplied, in strict confidence, to the DMC, together with any other analyses the DMC members requested.
Meetings of the committee were arranged periodically, as considered appropriate by the chairperson.
In the light of interim data, and other evidence from relevant studies (including updated overviews of the
relevant RCTs), the DMC agreed to inform the TSC if, in its view, there was proof beyond reasonable doubt
that the data indicated that any part of the protocol under investigation was either clearly indicated or
clearly contraindicated, either for all women or for a particular subgroup of trial participants. A decision to
inform the TSC would be based on statistical, clinical and ethical considerations.
The TSC and DMC members met jointly on two occasions: once at the beginning of the project before
recruitment started, to review and comment on the protocol and data collection instruments, and to agree
the TSC and DMC charters, and then again at the end of the project to agree the final analysis and
provide feedback to the investigators about interpretation of the findings.
Clinical Investigators Group
The Clinical Investigators Group (CIG) comprised the chief investigator, co-applicants (including a lay
member), clinical investigators from selected study sites, trial health economists and the trial statistician.
Appendix 6 lists the membership of the TSC, the DMC and the CIG.
Serious adverse event reporting
Serious adverse events were reported to the University College London (UCL) Trial Co-ordinating Office
within 48 hours. The Trial Co-ordinating Office notified the chairperson of the DMC and the REC. All
SAEs occurring during the trial observed by the investigator or reported by the participant, whether or
not attributed to the trial, were reported on the DCB. SAEs considered to be related to the trial by the
investigator were followed up until resolution or until the event was considered stable. The local investigator
was asked to provide follow-up information when necessary. All related SAEs that could have resulted in a
participant’s withdrawal from the trial, or which were present at the end of the trial, were followed up until
a satisfactory resolution occurred.
The chief investigator submitted to the REC, once a year throughout the clinical trial, a safety report that
included all SAEs.
Data handling, checks, cleaning and processing
All data collection forms (i.e. DCBs, HLC forms, maternal satisfaction and 1-year follow-up forms) and consent
forms, once completed and returned to the UCL Comprehensive Clinical Trials Unit (CCTU), were logged as
METHODS
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received and date stamped. Data were double entered at the UCL CCTU using the study database, by
independent data clerks. Validation routines checked for missing data and inconsistencies on an ongoing
basis. This included screening for out-of-range data, with cross-checks for conflicting data within and
between data collection forms using computerised logic-checking screens. Any validation errors on the DCBs
and HLC forms were queried and documented. Queries were communicated to the appropriate centres by
the trial manager. Errors on the maternal satisfaction questionnaire and the 1-year follow-up form were not
queried with the woman.
Cost-effectiveness analysis
An economic evaluation was conducted as part of this trial and is reported in detail in Chapter 6.
Patient and public involvement
When the initial investigator group was being assembled to develop the trial, the National Childbirth Trust
was approached to suggest a lay member who would be willing to join the group as a co-investigator.
Mary Nolan agreed to join the group, and assumed equal membership of the co-investigator group at all
planning meetings and trial conduct meetings, and in the drafting of the application, developing the detailed
trial protocol and data collection forms, and report and paper writing. Mary took a lead in helping the team
to develop participant information leaflets to be used in the antenatal period and at the time of labour, as
well as helping to plan dissemination activities and drafting and developing the summary information for the
public. During the course of the trial, Mary Nolan left the NCT to take up a position as Professor of Perinatal
Education at the University of Worcester, but continued to represent the potential participant’s perspective in
all aspects of the trial development, conduct and analysis.
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Chapter 3 Analysis plan
The statistical analysis plan (SAP) was written and approved before unblinding the data for statisticalanalysis (see Appendix 7). The SAP provided details of the presentation and analysis of the results from
the trial. The principles set out in the SAP were not intended to curtail exploratory analysis (e.g. to decide
cut-off points for categorisation of continuous variables) or to prohibit accepted practices (e.g. data
transformation prior to analysis), but they were intended to establish the rules that were followed,
as closely as possible, when analysing and reporting the trial.
Any deviations from the SAP are described and justified in this report.
Patient groups for analysis
Losses to the trial post randomisation were defined as any of the following:
l women for whom a valid consent form was not received
l women for whom consent to use their data was withdrawn
l women not in the second stage of labour when randomised and who did not reach the second stage
before delivery
l women not in labour or without an epidural in place at the time of randomisation.
The numbers (with percentages of the randomised population) of post-randomisation exclusions are
reported by randomised treatment group, and the reasons summarised.
Women could specify whether or not data collected up to the point of withdrawal could be used. If the
response was ‘no’, then they were counted as post-randomisation exclusions. If the response was ‘yes’,
then they were reported as ‘missing’ for all subsequent outcomes.
For the primary analysis, participants were analysed in the groups into which they were randomly allocated,
that is, comparing the outcomes of all women and infants for women allocated to a policy of an upright
position with those of women allocated to a policy of lying down, regardless of position recorded at any
time during the second stage of labour. Losses to the trial post randomisation are excluded from all
analyses, with the exception of the safety-reporting population, which excluded women for whom a valid
consent form was not received and women who withdrew and did not consent to use of their data.
The unit of analysis was the woman for all maternal outcomes and the infant for all infant outcomes.
Descriptive analyses
The flow of participants through each stage of the trial is summarised using a Consolidated Standards of
Reporting Trials (CONSORT) diagram (see Figure 8). Specifically, for each intervention group we report the
numbers of women randomly assigned and women for whom the incorrect allocation was recorded in the
eligibility section of the DCB. The number of ineligible women randomised is reported, with reasons for
ineligibility. The number of post-randomisation exclusions and women analysed for the primary outcome is also
reported. We report numbers for the 1-year follow-up, women lost to follow-up and women who withdrew
before 1 year. The total number of eligible women was not collected during the conduct of this study, as it
was considered too great a burden for the participating centres and would not be sufficiently reliable.
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Numbers (with percentages) for binary and categorical variables and means (and SDs) or medians (with
lower and upper quartiles), or geometric means for continuous variables are presented; no tests of
statistical significance were performed, nor CIs calculated, for differences between randomised groups on
any baseline variable.
The number (with percentages) of losses to follow-up among women selected for the 1-year assessment is
reported in the CONSORT flow chart by trial arm, and the reasons reported. Selected demographic and
clinical characteristics, the primary outcome and selected short-term outcomes of women and their infants
with 1-year data available were compared with those without 1-year data.
Missing data for primary and secondary outcomes, from baseline to the end of follow-up, are summarised
for the two trial arms. Not all data were routinely collected by all hospitals; for example body mass index
(BMI), cord artery pH and base deficit were sometimes omitted. The DCB allowed midwives to tick ‘data
not recorded’. These data are summarised by trial arm and reported separately from data missing or
unknown. Missing data for the primary outcome were negligible. If any data items were missing on the
DCBs, every effort was made to extract these data from the hospital involved.
Primary effectiveness analyses
Outcomes are summarised by trial arm using counts and percentages for categorical variables, means and
SDs for normally distributed continuous variables or medians and interquartile ranges for other continuous
variables. In addition, geometric means are presented for durations of stages of labour, as these are
inherently highly skewed data.
An adjusted analysis was performed on all comparative analyses adjusting for centre (the stratification factor
at randomisation) as a random effect. Binary outcomes were analysed using log-binomial regression models
and results presented as adjusted RRs with corresponding CIs. If the model did not converge, then
log-Poisson regression models with robust variance estimation were used.33 If the model was still unstable,
then the centre was removed and unadjusted RRs presented. Continuous outcomes were analysed using
linear regression models and results presented as adjusted differences in means with associated CIs.
Unadjusted Hodges–Lehmann34 median differences (plus CIs) for skewed continuous variables are presented.
The estimates are based on a difference between distributions. The Hodges–Lehmann median difference is
calculated by forming all possible differences between the first treatment group and the second treatment
group, and taking the median of those differences.
In addition, geometric mean ratios (GMRs) are presented for durations of the stages of labour as the
distribution of these data is highly skewed. A geometric mean is a measure of central tendency that is
based on the product of values (as opposed to an arithmetic mean that sums the values). A ratio of
geometric means provides an indication of how large one geometric mean is relative to another.
Comparisons between randomised groups of all primary and secondary outcomes are reported in full for
completeness and transparency, that is, there is no selective reporting of outcomes.
In order to take account of the number of comparisons, 95% CIs are presented for the primary outcome
and 99% CIs for all other outcomes.
Description of adherence to allocation
As described in Chapter 2, Data collection schedule, a record was made every 15 minutes of the woman’s
position ‘for the majority of the time since the last assessment’, and if this position had changed from the
previous assessment the reasons for this change were recorded. Reasons for a change from a woman’s
allocated position were recorded as free text.
ANALYSIS PLAN
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Positions recorded on the DCB were categorised according to whether or not the women were ‘lying
down’, ‘upright’ or in ‘other’ positions for each 15-minute interval. For each interval, the categorised
position was compared with the position allocated for the woman, and if the allocated position was the
same as the categorised position then that 15-minute interval was coded as ‘adherent’. All other positions
were coded as ‘non-adherent’. Some manual coding was required for positions recorded as text. Positions
recorded as lithotomy were categorised as ‘lying down’ as the pelvis was in a horizontal position.
A summary of adherence to allocated position is reported by trial arm for (1) the passive second stage
(i.e. before pushing commenced); (2) the active second stage (i.e. pushing); and (3) the whole of the
second stage. Summaries of adherence data are calculated as the proportion of 15-minute intervals a
woman spends in the position to which she was allocated out of the total number of 15-minute intervals
recorded in the passive, active or whole of the second stage of labour. Medians and interquartile ranges
are presented owing to the skewed distribution of the data.
Hodges–Lehmann differences in medians with corresponding 95% CIs are presented by randomised group.
There are a variety of reasons why women change from their allocated position. Changing position to allow
fetal blood sampling to be performed, to improve effective fetal heart rate monitoring, was considered ‘clinically
unavoidable’. All reasons for change were reviewed and classified as clinically avoidable or unavoidable in
accordance with these criteria. The analysis was performed for adherence by dealing with periods in which
changes to a non-allocated position were considered necessary for ‘clinically unavoidable reasons’ as adherent.
Reasons for change from allocated position were coded by the trial statistician and an independent
assessor, and are presented by trial arm using counts and percentages.
The self-completed maternal satisfaction questionnaire included a question asking the woman to record
what position she was in for the majority of the time during the passive and active stages of labour with
possible responses being ‘lying down’, ’upright’, ‘other’ and ‘can’t remember’. These data have been
summarised by trial arm using counts and percentages along with 95% CIs for differences in percentages.
A qualitative comparison has been made between these results and the results from the DCB data
provided by the midwife, to ascertain the extent to which reporting bias may have occurred, if at all.
Additional effectiveness analyses
The primary analysis was adjusted further for the primary outcome (pre-specified in the SAP) to investigate
the impact of the following known prognostic factors (in addition to centre): age as a continuous variable,
ethnicity, diagnosis of delay and onset of labour (induced vs. spontaneous).
To examine whether or not the effect of policy of position during the second stage of labour was consistent
across specific subgroups of women, the following prespecified subgroup analyses were undertaken:
l gestational age (37+0 to 38+6 weeks; 39+0 to 40+6 weeks; and ≥ 41+0 weeks)
l maternal age (≤ 24 years, 25–29 years, 30–34 years and ≥ 35 years)
l augmentation with oxytocin (Syntocinon®; Novartis Pharmaceuticals UK Ltd, Frimley/Camberley, UK) in
the first stage of labour (yes/no)
l Index of Multiple Deprivation (IMD; population-based quintiles 1–5; derived using the postcode of the
woman’s last known address based on the Indices of Multiple Deprivation 201035 and Ordnance Survey
Code-Point Open36 February 2013).
For the trial primary outcome, results are presented as forest plots showing the RR plus 95% CI for each
subgroup,37 by intervention group, with the p-value for the statistical test of interaction.38 Centre was
included as a stratifying factor in the list of subgroup analyses in the original protocol, as we were expecting
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to recruit to target using five centres only. Recruitment rates were poor and we expanded the number of
recruiting centres to 41. A subgroup analysis on 41 centres was therefore not considered relevant.
A prespecified sensitivity analysis on the 1-year maternal outcomes was carried out on a restricted data
set that excluded all women who were pregnant or had another child at the time of completing the
follow-up questionnaire.
Statistical software
Stata/SE® for Windows version 13.1 (StataCorp LP, College Station, TX, USA) was used for all analyses.
Reliability
All outcome data, except for maternal satisfaction questionnaire data and 1-year questionnaire data,
were recorded in the women’s hospital notes. Site-monitoring visits verified a random sample of data
collected on the DCBs and HLC forms, by making comparisons with information recorded in hospital
notes. Self-administered forms were not verified.
Data relating to the calculation of the process outcomes (i.e. maternal position at 15-minute intervals since
study entry) were recorded by the midwife on the DCB only, and the DCB was itself the source documentation
and can therefore not be verified directly with any other source. The maternal satisfaction questionnaire aimed
to confirm these data with a question asking the women to record what position they were in for the majority
of the time during the passive and active stages of labour.
The coding of position data and reasons for a change from allocated position recorded as text were
validated by an independent clinician.
Protocol violations and deviations
A protocol violation is a failure to comply fully with the final study protocol as approved by the REC and
research department, such as a serious non-compliance with the protocol resulting from error, fraud or
misconduct, and results in the exclusion of a patient from the analysis for the study. There were no
protocol violations.
A protocol deviation is a departure from the final study protocol as approved by the REC, with minor
consequences on the integrity of the data. Protocol deviations are those that resulted in exclusion from the
analysis reported in Chapter 5 (see Figure 8). There was only one other protocol deviation, and that was
unrecognised at the time of randomisation; the woman had intrathecal analgesia.
ANALYSIS PLAN
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Chapter 4 Trial conduct
There were two major challenges during the conduct of the trial: recruitment and monitoring ofadherence to the intervention. These are explained below.
Recruitment
Trial recruitment was initially planned to be undertaken in the maternity units of four acute NHS trusts in
England and one health board in Wales. The BUMPES study design originally outlined in the trial protocol
described a single-centre internal pilot study to assess feasibility, develop teaching materials and field-test
trial data collection processes. After 9 months of the pilot phase, it was noted that, although the trial
infrastructure and data capture were satisfactory, accrual did not meet projected targets, despite accurate
predictions of available participants. At the recommendation of the TSC, the trial was initiated at a second
pilot site prior to ‘roll-out’, in order to establish if these limitations were site specific or reflected broader
barriers to recruitment. It was noted that recruitment across the two pilot centres remained unsatisfactory,
with an average of 49% of the overall recruitment target being met over the 6 months since the second
pilot site opened to recruitment (Figures 4 and 5).
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FIGURE 5 Recruitment at second pilot centre.
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Challenges to study recruitment
Equipoise
Engagement with clinical midwifery staff for feedback and exploration of obstacles to recruitment was
repeatedly sought. Initially this process revealed a lack of equipoise regarding the trial intervention in some
individuals. While unsupported by evidence, this was a powerful perceptual obstacle, which may in part
have resulted from sources of conflicting information. As described earlier, the NICE Intrapartum Care
Guidelines (2007)31 stated that:
Women with regional analgesia should be encouraged to move and adopt whatever upright position
they find comfortable throughout labour.
NICE Clinical Guidelines, No. 190 (section 1.5.7, p. 22)31
These recommendations acknowledged that current evidence was inadequate and did not favour any specific
positions. However, it is possible that misinterpretation of these guidelines could have affected equipoise and
accounted for the perception that a particular position confers an advantage in birth outcomes. It may also
explain the initial reluctance of midwives on the labour wards to identify with the study.
During the study, when women were approached to participate, they readily agreed. Thus there was
nothing to suggest that those women who consented represented a distinct population that could reduce
the generalisability of the trial findings. Furthermore, women in labour appeared to have genuine equipoise
with respect to the intervention. Continued feedback to midwives and further training emphasised the
importance of equipoise in order for the research to generate a definitive answer to the research question.
Clinical issues
Consent
Local R&D departments at participating units insisted that the clinical midwives attending women in labour
required good clinical practice (GCP) training in order to take informed consent. The initiation visit allowed
these issues to be explored and addressed locally either by arranging GCP training for midwives working
on the labour wards or arranging for anaesthetists/research staff to be contacted to take consent. This
inevitably led to delays in initiating recruitment and an ongoing barrier to recruitment, as most staff were
not GCP trained, and many felt that this was unnecessary.
Competing studies
During the recruitment phase, several hospitals introduced other intrapartum studies, for which consent had
been gained in the antenatal period or in early labour. The local staff felt that women could not be recruited
to more than one study in the intrapartum period and midwives therefore did not approach these women.
As a consequence of these challenges, a decision was made that participation in the study should be
expanded to more centres, in addition to the original five proposed.
Recruitment strategies
During the whole period of recruitment, a number of initiatives were launched to improve recruitment.
These included:
l Timing of informed consent. During the pilot phase, it was noted that gaining informed consent in the
second stage of labour (from full dilatation of the cervix to birth of the baby) was delaying time to
randomisation and therefore study entry. As the second stage of labour is a clinically demanding time on
labour wards, this could potentially be a barrier to recruitment. Following approval (REC amendment 4,
25 July 2011), consent could be sought and obtained from potential study participants in the first stage
TRIAL CONDUCT
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of labour, once an effective epidural had been administered. Randomisation had to be delayed until the
second stage of labour had been confirmed, but this process alleviated the burden of recruitment for the
attending midwife.
l To recruit at more sites. Following a proposal from the CIG and agreement from the TSC, there was
approval to recruit a further 36 maternity units, which were opened to recruitment over a 24-month
period (a total of 41 hospitals). Additional units that had a good track record of participation in health
research in pregnancy were approached, along with hospitals that had already expressed an interest in
participating. An initiation visit from the research midwife in the BUMPES team was arranged to fully
explain the study to lead midwives, anaesthetists and local R&D departments, and also to evaluate their
enthusiasm and the level of support that they would offer the study. Following R&D approvals, dates
were arranged for the research midwife to attend the maternity units, and provide training to staff and
support them during initial recruitment. This usually took 1 full week, covering day and night shifts, and
involved small groups of midwives and anaesthetists. A training manual, posters, recruitment packs and
randomisation flow charts, as well as 24-hour contact details, were in place for all centres prior to the
start of recruitment. Further training was also provided to many units on request to support recruitment.
l Change to funding model. Initially, BUMPES provided funding to appoint a ‘BUMPES midwife’ at each
of the original five maternity units for 2 days per week. Their role was to support training, recruitment,
data collection and the day-to-day running of the study. With the involvement of 36 more maternity
units, the existing funding model was unsustainable within the trial budget, so this was changed to a
‘payment-per-recruit’ model (£85) for each of the maternity units. This proposal was approved by both
the TSC (9 December 2011) and the NIHR HTA programme, and was in place from January 2012.
l Development of local BUMPES champions and Comprehensive Local Research Network (CLRN) support
(England). Given the change in the funding model, and the loss of specific BUMPES midwives, a revised
model of local support was designed. This involved the introduction of BUMPES champions. Clinical
midwives active on each labour ward shift were identified to promote the study, identify potential
recruits, facilitate consent and support randomisation. This ensured that, as much as possible, someone
was available who was knowledgeable about the trial and able to support recruiting midwives. This was
supported in some units with extra CLRN funding and in others by the payment-per-recruit monies.
l DCBs. Following feedback from the units, the DCBs were redesigned. Staff complained that DCBs were
too long and the amount of information requested was too much, so that, on a busy labour ward shift,
midwives were put off recruiting or completing the booklets. The DCBs were redesigned into parts 1
and 2. Part 1 was reduced to a single-page A3 worksheet and was the only section that the attending
midwife during labour needed to complete. This requested information that could not be collected
at a later date, for example visual analogue scale score (pain assessment), the date and time when the
woman adopted the allocated position, times and positions every 15 minutes and reasons for change.
CLRN and the National Institute for Social and Health Research [(NISCHR) Wales] research staff or staff
employed using the BUMPES payment per recruit monies were able to complete part 2 at a later date
with information from the maternal and neonatal notes.
l Increasing midwifery ownership. A short article to raise awareness was published in the Royal College
of Midwives Journal (2012). This was designed to encourage midwifery ownership of the study and the
importance of the results, which could potentially have an impact on future midwifery practice and be
beneficial to women. A Collaborators’ Study Day for recruiting units was arranged in November 2012
to improve networking, and for sharing ideas and identifying areas of good practice. This was attended
by 34 midwives from 18 participating centres and feedback from the day was excellent.
l Promoting BUMPES. Life-sized posters and other promotional items were designed and, when required,
received REC approval. This helped to encourage promotion of the study to midwives, women and
antenatal educators.
l Recruitment updates and newsletters. Recruitment updates were sent to units monthly. Newsletters were
published quarterly and included recruitment targets, the identity of new participating units and answers
to frequently asked questions, to help improve awareness and address common errors and queries.
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l Incentives. Approved incentives for midwives such as fob watches, notebooks, Post-it® (3M, Cynthiana,
KY, USA) notes, mugs, key rings, pens, tape measures, lanyards and lip gels were purchased and given
during training sessions. This helped to identify and promote contact details of the study. Occasional
gift vouchers were approved and given to support recruitment as well as seasonal gifts, such as Love
Hearts (Swizzels Matlow, New Mills, Stockport, UK) for Valentine’s Day, Easter eggs, summer rock
candy, Halloween-themed sweets and an advent calendar in December.
The combination of marketing the trial more actively and participation of the additional centres resulted
in a substantial improvement in recruitment. The project management group continued to monitor
recruitment closely throughout the trial. An example of the monitoring data reviewed is shown in Table 3
and Figure 6.
However, the delays inherent in establishing the participation of a greater number of centres resulted in a
request to the NIHR HTA programme for a 12-month extension of the trial. This no-cost extension was
granted in September 2013.
TRIAL CONDUCT
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TABLE 3 Study recruitment details from March 2012 to February 2013
Recruitment
Month, grand totals
March
2012
April
2012
May
2012
June
2012
July
2012
August
2012
September
2012
October
2012
November
2012
December
2012
January
2013
February
2013
Monthly targets 25 44 63 75 90 111 114 141 164 176 188 192
Monthly recruitment 14 28 47 59 75 72 68 95 132 126 118 133
Monthly target achieved (%) 56 64 75 79 83 65 60 67 80 72 63 69
Target cumulative total 469 514 569 634 711 800 901 1014 1139 1276 1425 1586
Actual cumulative total 216 244 291 350 425 497 565 660 792 918 1036 1169
Overall percentage of target 46 47 51 55 60 62 63 65 70 72 73 74
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FIGURE 6 Study recruitment details from March 2012 to February 2013.
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Chapter 5 Results
Between 4 October 2010 and 31 January 2014, 3236 women were randomised to the BUMPES trialfrom 41 participating centres (Figure 7).
In accordance with the prespecified SAP, 143 women (4.4%) met the criteria to be excluded from the
analysis of the primary outcome. The majority of these exclusions were because of missing or incomplete
consent forms. For 32 women, exclusion was because they were randomised in error (19 were not in the
second stage of labour at the time of randomisation and never reached the second stage of labour, having
caesarean section prior to full dilatation of the cervix, and 12 were apparently randomised after delivery).
These are detailed in the participant flow diagram (Figure 8). DCBs were available for all women recruited
and analysed. Follow-up at 1 year was achieved for 61% of women (see Figure 8).
Baseline characteristics were similar between the two arms of the trial (Table 4). Mean maternal age was
28.4 years (SD 5.6 years). The majority of women in both arms had a gestational age of between 37 and 41
completed weeks, although 7.5% of women were at ≥ 42 weeks. The vast majority of women participating
in the trial were of white ethnic origin and mean BMI at booking was just over 25 kg/m2. Approximately
40% of women had their labour induced, which is higher than might be expected in the general maternity
population.40 However, as recruited women all had epidural analgesia, which is associated with longer and
more painful labours, as is induction of labour, this proportion does not appear excessive. Similarly, 50% of
women had augmentation with oxytocin during their labour, which is compatible with women requesting
epidural analgesia because of a longer labour.40
Approximately 80% of women were able to perform a straight leg raise at the time of trial entry,
suggesting that these women had reasonable mobility with their epidural analgesia.
There is an apparent disparity between the two groups in the position of the women at the time of trial entry.
It appears that there was a higher proportion of women who were lying down in the group allocated to lying
down than for women allocated to the upright position. The way these data were requested could have led
to misclassification of this variable, in that midwives may have recorded the position of the women at the
time of allocation, that is, after they had already assumed the allocated position. As all other characteristics of
the women were similar at baseline, it appears very unlikely that this would represent the true position at the
time of randomisation; rather, it would be a combination of this plus actual allocation.
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Randomised
(n = 3236)
Allocated to ‘lying-down’ position
(n = 1613)
• Opposite intervention documented on DCB, n = 14
• Not known if allocated intervention, n = 32
Analysed for the 1-year follow-up
n =  942/1537 (61.3%) 
Analysed for the primary outcome
(n = 1537)
Excluded from analysis (n = 76):
• consent form missing/incomplete, n = 55
• consent to use data withdrawn, n = 4
• randomised in error, n = 17
   • no second stage of labour, n = 9
   • epidural analgesia not in place at randomisation, n = 0
   • randomised after delivery, n = 8
Lost to follow-up
(n = 595)
• Questionnaires not returned, n = 511
• Not contactable, n = 6
• Living at different address to infant, n = 48
• Declined to be followed up, n = 4
• 3-month window expired,a n = 25
• Stillbirth/infant death, n = 1
• Other reason, n = 0
Allocated to ‘upright’ position
(n = 1623)
• Opposite intervention documented on DCB, n = 6
• Not known if allocated intervention, n = 27
Analysed for the 1-year follow-up
n =  950/1556 (61.1%)
Analysed for the primary outcome
(n = 1556)
Excluded from analysis (n = 67):
• consent form missing/incomplete, n = 49
• consent to use data withdrawn, n = 3
• randomised in error, n = 15
   • no second stage of labour, n = 10
   • epidural analgesia not in place at randomisation, n = 1
   • randomised after delivery, n = 4
Lost to follow-up
(n = 606)
• Questionnaires not returned, n = 528
• Not contactable, n = 8
• Living at different address to infant, n = 43
• Declined to be followed up, n = 2
• 3-month window expired,a n = 20
• Stillbirth/infant death, n = 1
• Other reason, n = 4
FIGURE 8 Participant flow diagram. a, If not contactable after 15 months since randomisation, then the questionnaire was not sent. Reproduced from The Epidural and
Position Trial Collaborative Group.39 This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which
permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/
by/4.0/.
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TABLE 4 Centre recruitment and characteristics of women prior to study entry
Characteristic
Trial arm
Upright (N= 1556) Lying down (N= 1537)
Centre, n (%)
Birmingham Women’s Hospital 116 (7.5) 118 (7.7)
St Thomas’ Hospital 237 (15.2) 241 (15.7)
Queen Alexandra Hospital, Portsmouth 43 (2.8) 42 (2.7)
University Hospital of Wales 150 (9.6) 146 (9.5)
Royal United Hospitals Bath 99 (6.4) 101 (6.6)
Bradford Royal Infirmary 58 (3.7) 55 (3.6)
Jessop Wing, Sheffield Teaching Hospital 93 (6.0) 94 (6.1)
Princess of Wales Hospital 22 (1.4) 19 (1.2)
Singleton Hospital, Swansea 19 (1.2) 18 (1.2)
Royal Gwent Hospital, Newport 29 (1.9) 25 (1.6)
Gloucestershire Royal Hospital 26 (1.7) 22 (1.4)
Nevill Hall Hospital 9 (0.6) 10 (0.7)
Frimley Park Hospital 97 (6.2) 96 (6.3)
Sunderland Royal Hospital 21 (1.4) 22 (1.4)
Pinderfields Hospital 36 (2.3) 36 (2.3)
Warrington Hospital 29 (1.9) 29 (1.9)
Tameside Hospital 26 (1.7) 24 (1.6)
Medway Maritime Hospital 15 (1.0) 10 (0.7)
South Tyneside District Hospital 8 (0.5) 7 (0.5)
Queen Mary’s Hospital, London 64 (4.1) 62 (4.0)
Queen Charlotte’s and Chelsea Hospital 7 (0.5) 11 (0.7)
Queen Elizabeth Hospital 24 (1.5) 21 (1.4)
Great Western Hospital 27 (1.7) 30 (2.0)
Royal Cornwall Hospital 19 (1.2) 20 (1.3)
Bedford Hospital 26 (1.7) 30 (2.0)
University College Hospital, London 18 (1.2) 13 (0.9)
Royal Sussex County Hospital 16 (1.0) 13 (0.9)
North Manchester General Hospital 30 (1.9) 28 (1.8)
New Cross Hospital, Wolverhampton 22 (1.4) 19 (1.2)
James Paget Hospital 21 (1.4) 23 (1.5)
St George’s Hospital 32 (2.1) 33 (2.2)
Princess Royal University Hospital 6 (0.4) 2 (0.1)
King’s College Hospital, London 39 (2.5) 41 (2.7)
St Mary’s Hospital 3 (0.2) 4 (0.3)
Dorset County Hospital 10 (0.6) 10 (0.7)
continued
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TABLE 4 Centre recruitment and characteristics of women prior to study entry (continued )
Characteristic
Trial arm
Upright (N= 1556) Lying down (N= 1537)
Kingston Hospital 41 (2.6) 46 (3.0)
Hillingdon Hospital 7 (0.5) 5 (0.3)
Arrowe Park Hospital 7 (0.5) 5 (0.3)
Lewisham Hospital 2 (0.1) 1 (0.1)
Prince Charles Hospital 2 (0.1) 5 (0.3)
Maternal age (years), n (%)
Mean (SD) 28.4 (5.7) 28.4 (5.6)
< 20 111 (7.1) 99 (6.4)
20–24 303 (19.5) 292 (19.0)
25–29 437 (28.1) 463 (30.1)
30–34 488 (31.4) 482 (31.4)
35–39 182 (11.7) 161 (10.5)
≥ 40 34 (2.2) 40 (2.6)
Missing 1 0
Gestational age at entry (weeks)
Mean (SD) 40.4 (1.2) 40.4 (1.2)
37+0 to 39+6, n (%) 482 (31.0) 500 (32.6)
40+0 to 41+6, n (%) 955 (61.5) 921 (60.0)
≥ 42+0, n (%) 116 (7.5) 115 (7.5)
Missing 3 1
IMD: quintile, n (%)
First (least deprived) 205 (16.0) 204 (16.0)
Second 182 (14.2) 201 (15.7)
Third 246 (19.2) 235 (18.4)
Fourth 349 (27.2) 345 (27.0)
Fifth (most deprived) 299 (23.3) 294 (23.0)
Wales – not derived 224 217
Postcode missing 51 41
Ethnic group, n (%)
White 1305 (84.5) 1275 (83.5)
Indian 48 (3.1) 57 (3.7)
Pakistani 26 (1.7) 30 (2.0)
Bangladeshi 6 (0.4) 3 (0.2)
Black African 28 (1.8) 30 (2.0)
Black Caribbean 14 (0.9) 11 (0.7)
Any other ethnic group 117 (7.6) 121 (7.9)
Not known/missing 12 10
RESULTS
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TABLE 4 Centre recruitment and characteristics of women prior to study entry (continued )
Characteristic
Trial arm
Upright (N= 1556) Lying down (N= 1537)
BMI at booking visit (kg/m2)
Mean (SD) 25.5 (5.4) 25.2 (5.3)
Height and/or weight not known 65 60
Woman undergone FGM, n (%) 6 (0.4) 1 (0.1)
Missing 6 7
Onset of labour, n (%)
Spontaneous 941 (60.6) 904 (58.9)
Induced 613 (39.5) 632 (41.2)
Missing 2 1
Duration of first stage (minutes)
Median (IQR) 510 (360–715) 495 (350–705)
Geometric mean 484.9 481.9
Missing 17 10
Diagnosis of pre-eclampsia, n (%) 52 (3.4) 52 (3.4)
Missing 5 3
Continuous electronic fetal monitoring, n (%) 1485 (95.5) 1470 (95.8)
Missing 1 2
Diagnosis of delay requiring intervention, n (%) 796 (51.2) 770 (50.2)
Missing 1 3
Systemic opioids given prior to epidural, n (%) 442 (28.4) 435 (28.3)
Pethidine 353 (79.9) 330 (75.9)
Diamorphine 77 (17.4) 88 (20.2)
Remifentanil 3 (0.7) 4 (0.9)
Morphine 0 (0.0) 0 (0.0)
Meptazin 12 (2.7) 17 (3.9)
Missing 1 1
Epidural technique, n (%)
Epidural 1492 (96.0) 1481 (96.4)
Combined spinal epidural 62 (4.0) 55 (3.6)
Missing 2 1
Epidural maintained with PCEA/infusion, n (%) 1224 (80.6) 1196 (79.9)
Missing 37 40
Woman’s pain score for last contraction
Median (IQR) 10 (0–30) 10 (0–38)
Missing 162 184
continued
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The time from randomisation to trial entry, and all other durations recorded in the results section, are
prone to errors because of time differences recorded in different parts of the labour ward. The time of
randomisation is accurate, as this was recorded by the randomisation service. However, all other times will
depend on the accuracy of the clocks in the different locations in the labour ward. For example, the clock
in the central midwifery station may read a slightly different time from that in the labour room, and these
may both be different from the clock in theatre. There were many (relatively minor) problems with derived
duration variables in the data set (e.g. negative values), suggesting variation in actual time recorded
between different settings.
There was a clear difference in the incidence of the primary outcome, SVB, between the groups, with
35.2% of women achieving a SVB in the upright group compared with 41.1% achieving a SVB in the
lying-down group [adjusted RR 0.86, 95% CI 0.78 to 0.94 (Table 5)]. This represents a 5.9% absolute risk
increase in the chance of a SVB in the lying-down group. The original and subsequently revised sample size
estimation aimed to detect a 5–6% absolute risk reduction.
TABLE 4 Centre recruitment and characteristics of women prior to study entry (continued )
Characteristic
Trial arm
Upright (N= 1556) Lying down (N= 1537)
Able to perform straight leg raise, n (%) 1162 (78.7) 1152 (80.2)
Missing 79 101
Position prior to study entry, n (%)
Lying down 432 (29.0) 546 (37.7)
Upright 977 (65.6) 832 (57.4)
Lithotomy 5 (0.3) 6 (0.4)
Semi-recumbent 58 (3.9) 53 (3.7)
Other 17 (1.1) 12 (0.8)
Missing 67 88
Time from VE diagnosing second stage to study entry (minutes)
Median (IQR) 16 (9–30) 16 (8–30)
Apparently randomised before diagnosis of second stagea 70 79
Time apparently > 180 minutesa 6 7
Missing 7 2
Time from study entry to start of recording positions (minutes)
Median (IQR) 1 (–2 to 6) 1 (–3 to 7)
Time from study entry to recording position > 15 minutes,b n (%) 154 (10.1) 150 (9.9)
Time apparently > 15 minutes before study entrya 227 218
Missing 30 27
Baby’s birth weight (grams)c
Mean (SD) 3500 (450) 3488 (442)
Missing 1 1
FGM, female genital mutilation; IQR, interquartile range; PCEA, patient-controlled epidural analgesia; VE, vaginal examination.
a Values set to missing for calculation of median and interquartile range.
b Values included for calculation of median and interquartile range.
c Measured after study entry but not an outcome.
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As specified in the SAP, the primary outcome analysis was further adjusted for the characteristics age,
ethnicity, the diagnosis of delay and the nature of the onset of labour (Table 6).
There was no evidence of a difference found for most of the secondary maternal outcomes after study
entry and during labour, particularly with respect to epidural drug dosage, use of augmentation, fetal
blood sampling or the use of fetal scalp electrodes (Table 7). There was a statistically significant difference
at the 1% level in the duration of the active second stage of labour with a shorter duration of labour in
the lying-down group (GMR 1.08 minutes, 99% CI 1.01 to 1.15 minutes).
Other secondary maternal outcomes, such as IVD and caesarean section, suggested an increased risk
associated with the upright position, but again these differences were not statistically significant at the 1%
level. For those women undergoing operative delivery (instrumental or caesarean section), the indications
appeared to be similar between the two arms of the trial. Just over one-third were reported to be caused
by fetal distress and nearly 60% caused by failure to progress.
With respect to genital tract trauma there was a suggestion that there may be an increase in the incidence
of episiotomy in the upright group compared with the lying-down group, although this was not significant
at the 1% level. There were no statistically significant differences in the risk of perineal trauma, although
there appeared to be a higher incidence of obstetric anal sphincter injury in the upright group (6.7%) than
in the lying-down group (5.3%), but again this difference was not statistically significant at the 1% level
(Table 8).
There was no evidence of a difference in maternal satisfaction in labour between the two arms of the trial,
although there were interesting findings with respect to women’s views about the care they received in
labour (Table 9). The majority of women ‘strongly agreed’ or ‘agreed’ with many of the statements, such as
their satisfaction with their overall childbirth experience, that they were treated with respect by all the staff
and that they were involved in decision-making during labour. However, in the case of factors such as
whether or not their expectations for labour and birth were met, or if they felt in control, the proportions of
women who ‘strongly agreed’ or ‘agreed’ were lower. Of particular interest in the context of BUMPES is
that less than half of women ‘strongly agreed’ or ‘agreed’ that they were able to move as much as they
wanted. Perhaps not surprisingly, the majority of women were satisfied with their pain relief during labour.
Infant outcomes were extremely good overall, with very few babies having a low Apgar score at 5 minutes
or evidence of metabolic acidosis (Table 10). There did appear to be more babies with metabolic acidosis in
TABLE 5 Primary outcome: SVB
Outcome
Trial arm
Adjusteda RR (95% CI)Upright (N= 1556), n (%) Lying down (N= 1537), n (%)
SVB 548 (35.2) 632 (41.1) 0.86 (0.78 to 0.94)
Missing 1 0 –
a Adjusted for centre.
TABLE 6 Adjusted analysis for the primary outcome
Primary outcome Adjusted RR (95% CI)
Full model:a adjusting for maternal age, ethnicity, diagnosis of delay and onset of labour 0.86 (0.79 to 0.94)
a Model adjusts for centre as a random effect.
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TABLE 7 Secondary maternal outcomes after study entry and during labour
Outcome
Trial arm
Adjusteda effect measure
(99% CI)
Upright
(N= 1556)
Lying down
(N= 1537)
Epidural drugsb administered after study entry, n (%) 832 (75.4) 862 (76.7) –
Missing 453 413
Total-dose local anaestheticb (mg)
Bupivacaine 814 849 Median difference 0 (–2 to 0)
Mean (SD) 26.4 (22.2) 26.7 (21.2)
Median (IQR) 20 (10–31) 20 (12–33)
Lidocaine 6 8 Median difference 0 (–100 to 180)
Mean (SD) 256.7 (88.0) 205 (99.6)
Median (IQR) 200 (200–360) 200 (180–250)
Ropivicaine 2 1 Median difference 0 (–23 to 23)
Mean (SD) 75 (31.8) 75
Median (IQR) 75 (53–98) 75 (75–75)
Total-dose opioidsb
Fentanyl (µg) 809 840 Median difference 0 (–4 to 0)
Mean (SD) 49.4 (39.0) 51.6 (41.6)
Median (IQR) 40 (20–60) 40 (22–64)
Diamorphine (mg) 4 1 Median difference 0 (0 to 0)
Mean (SD) 3.0 (0.0) 3.0
Median (IQR) 3 (3–3) 3 (3–3)
Hypotension (systolic BP of < 100mmHg), n (%) 42 (2.7) 49 (3.2) RR 0.85 (0.50 to 1.44)
Missing 3 4
Vasopressors to increase blood pressure, n (%) 13 (0.8) 12 (0.8) RR 1.07 (0.39 to 2.99)
Missing 3 2
Syntocinon for augmentation, n (%) 172 (11.1) 163 (10.6) RR 1.04 (0.80 to 1.35)
Missing 3 2
Fetal blood sampling performed, n (%) 90 (5.8) 72 (4.7) RR 1.17 (0.82 to 1.68)
Missing 4 3
Fetal scalp electrode applied, n (%) 94 (6.1) 85 (5.6) RR 1.09 (0.76 to 1.57)
Missing 6 11
Duration of active second stagec (minutes)
Geometric mean 80.9 75.0 GMR 1.08 (1.01 to 1.15)
Median (IQR) 94 (56–133) 88 (51–126) Median difference 6 (1 to 11)
Missing 14 12
Total duration of second staged (minutes)
Geometric mean 130.5 125.1 GMR 1.04 (0.98 to 1.10)
Median (IQR) 149 (100–197) 141 (95–188) Median difference 7 (0 to 13)
Missing 6 0
BP, blood pressure; IQR, interquartile range.
a Adjusted for centre.
b Includes ‘top-up’ and/or patient-controlled epidural anaesthesia.
c Defined as the time from when pushing commenced until birth.
d Defined as the time from study entry until birth.
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TABLE 8 Secondary maternal outcomes at and immediately post delivery
Outcome
Trial arm
Adjusteda effect measure
(99% CI)
Upright
(N= 1556)
Lying down
(N= 1537)
Mode of delivery, n (%)
IVDb 849 (54.6) 778 (50.6) RR 1.08 (0.99 to 1.18)
Forceps 578 (37.2) 503 (32.7)
Ventouse 271 (17.4) 275 (17.9)
Caesarean sectionc 158 (10.2) 127 (8.3) RR 1.23 (0.92 to 1.64)
Categoryd of caesarean section
1 54 (34.2) 33 (26.0)
2 95 (60.1) 81 (63.8)
3 9 (5.7) 13 (10.2)
Missing 1 0
Primary indication for assisted (non-spontaneous) delivery, n (%)
Instrumental
Fetal distress 338 (39.9) 304 (39.1)
Failure to progress 504 (59.4) 468 (60.2)
Other 6 (0.7) 5 (0.6)
Missing 1 1
Caesarean section
Fetal distress 39 (24.7) 32 (25.2)
Failure to progress 118 (74.7) 94 (74.0)
Other 1 (0.6) 1 (0.8)
Anaesthesia required for instrumental/caesarean
section delivery,e n (%)
587 (58.5) 515 (57.4) RR 1.03 (0.95 to 1.12)
Technique usedf
Local infiltration 65 (11.1) 94 (18.3)
Pudendal block 16 (2.7) 16 (3.1)
High-dose epidural top-up 439 (74.8) 342 (66.4)
Spinal anaesthesia 68 (11.6) 72 (14.0)
General anaesthesia 11 (1.9) 6 (1.2)
Missing 4 7
Active management of third stage, n (%) 1450 (98.0) 1432 (98.2) RR 1.00 (0.91 to 1.10)
Missing 76 78
Genital tract trauma, n (%)
Episiotomy performed 914 (58.8) 838 (54.6) RR 1.07 (0.99 to 1.16)
Missing 1 1
Perineal tear evident, including perineal tear
with episiotomy
759 (48.9) 785 (51.1) RR 0.95 (0.87 to 1.04)
Missing 4 1
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TABLE 8 Secondary maternal outcomes at and immediately post delivery (continued )
Outcome
Trial arm
Adjusteda effect measure
(99% CI)
Upright
(N= 1556)
Lying down
(N= 1537)
Severity,g n (%)
1 90 (11.9) 96 (12.2)
2 563 (74.4) 608 (77.5)
3a 49 (6.5) 53 (6.8)
3b 33 (4.4) 17 (2.2)
3c 16 (2.1) 7 (0.9)
4 6 (0.8) 4 (0.5)
Missing 2 0
Obstetric anal sphincter injuryh 104 (6.7) 81 (5.3) RR 1.27 (0.88 to 1.84)
Perineum sutured, n (%) 1284 (82.6) 1248 (81.4) RR 1.02 (0.92 to 1.12)
Missing 2 3
Anterior tear evident and sutured, n (%) 102 (6.6) 107 (7.0) RR 0.95 (0.67 to 1.33)
Missing 7 4
Manual removal of the placenta performed, n (%) 99 (6.5) 101 (6.7) RR 0.97 (0.69 to 1.38)
Missing 28 35
Post-partum haemorrhage requiring blood
transfusion, n (%)
63 (4.1) 52 (3.4) RR 1.20 (0.75 to 1.93)
Units transfused,i mean (SD) 2.6 (1.5) 2.2 (1.0) MD –0.34 (–0.94 to 0.27)
Missing 1 1
Woman’s pain score for birth
Median (IQR) 15 (0–50) 10 (0–50) Median differencej 0 (0 to 0)
Missing 345 347
Length of inpatient stay after delivery (hours)
Median (IQR) 38.7 (24.9–59.7) 37.5 (24.2–56.5) Median differencej –1.2
(–3.2 to 0.7)
Missing 48 34
IQR, interquartile range; MD, mean difference.
a Adjusted for centre.
b Compared with no IVD.
c Compared with no caesarean section.
d Royal College of Obstetricians and Gynaecologists classifications: (1) immediate threat to life of woman or fetus;
(2) threat of maternal or fetal compromise; (3) no threat of compromise but needs early delivery.
e Anaesthesia additional to the routine epidural pain relief given in labour.
f Categories are not mutually exclusive.
g Degree of severity according to NICE intrapartum guidelines:31 (1) injury to skin only; (2) injury to perineal muscles but
not anal sphincter; (3) injury to perineum involving anal sphincter complex [(i) < 50% of external anal sphincter thickness
torn; (ii) > 50% of external anal sphincter thickness torn; and (iii) internal anal sphincter torn]; and (4) injury to perineum
involving anal sphincter complex and anal epithelium.
h Severity grades 3 and 4.
i In women who had blood transfused.
j Not adjusted for centre.
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TABLE 9 Maternal satisfaction
Outcome
Trial arm
RRa,b (99% CI)Upright (N= 1556), n (%) Lying down (N= 1537), n (%)
Number of questionnaires returned 1208 (77.6) 1165 (75.8) –
Satisfied with overall childbirth experience 0.97 (0.92 to 1.01)
Strongly agree 553 (47.2) 539 (47.1)
Agree 410 (35.0) 434 (37.9)
Neutral 114 (9.7) 100 (8.7)
Disagree 65 (5.6) 40 (3.5)
Strongly disagree 30 (2.6) 31 (2.7)
Missing 36 21
Treated with respect by all staff 1.01 (0.99 to 1.02)
Strongly agree 968 (82.0) 937 (81.3)
Agree 178 (15.1) 176 (15.3)
Neutral 19 (1.6) 20 (1.7)
Disagree 7 (0.6) 11 (1.0)
Strongly disagree 8 (0.7) 8 (0.7)
Missing 28 13
Involved in making decisions 0.99 (0.96 to 1.02)
Strongly agree 824 (69.9) 788 (68.5)
Agree 278 (23.6) 299 (26.0)
Neutral 56 (4.8) 45 (3.9)
Disagree 11 (0.9) 10 (0.9)
Strongly disagree 10 (0.9) 9 (0.8)
Missing 29 14
Expectations for labour and birth were met 1.00 (0.93 to 1.08)
Strongly agree 444 (38.0) 437 (38.2)
Agree 359 (30.7) 346 (30.2)
Neutral 209 (17.9) 207 (18.1)
Disagree 118 (10.1) 113 (9.9)
Strongly disagree 40 (3.4) 41 (3.6)
Missing 38 21
Felt safe at all times 1.01 (0.98 to 1.04)
Strongly agree 793 (67.4) 773 (67.2)
Agree 312 (26.5) 299 (26.0)
Neutral 39 (3.3) 51 (4.4)
Disagree 24 (2.0) 16 (1.4)
Strongly disagree 9 (0.8) 11 (1.0)
Missing 31 15
Good communication from staff 1.01 (0.99 to 1.03)
Strongly agree 913 (77.3) 864 (75.3)
Agree 222 (18.8) 230 (20.0)
Neutral 30 (2.5) 33 (2.9)
Disagree 9 (0.8) 10 (0.9)
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TABLE 9 Maternal satisfaction (continued )
Outcome
Trial arm
RRa,b (99% CI)Upright (N= 1556), n (%) Lying down (N= 1537), n (%)
Strongly disagree 7 (0.6) 11 (1.0)
Missing 27 17
Felt in control 1.01 (0.94 to 1.08)
Strongly agree 428 (36.4) 426 (37.2)
Agree 396 (33.6) 368 (32.1)
Neutral 223 (19.0) 232 (20.2)
Disagree 105 (8.9) 93 (8.1)
Strongly disagree 25 (2.1) 27 (2.4)
Missing 31 19
Able to move as much as wanted 0.95 (0.85 to 1.06)
Strongly agree 283 (24.5) 310 (27.2)
Agree 285 (24.7) 279 (24.5)
Neutral 239 (20.7) 236 (20.7)
Disagree 253 (21.9) 228 (20.0)
Strongly disagree 95 (8.2) 86 (7.6)
Missing 53 26
Satisfied with position before pushing 1.03 (0.99 to 1.07)
Strongly agree 590 (50.3) 566 (49.4)
Agree 460 (39.2) 430 (37.5)
Neutral 83 (7.1) 83 (7.2)
Disagree 29 (2.5) 52 (4.5)
Strongly disagree 12 (1.0) 15 (1.3)
Missing 34 19
Satisfied with position while pushing 1.02 (0.98 to 1.06)
Strongly agree 613 (52.2) 570 (49.8)
Agree 425 (36.2) 422 (36.9)
Neutral 94 (8.0) 91 (8.0)
Disagree 29 (2.5) 48 (4.2)
Strongly disagree 13 (1.1) 14 (1.2)
Missing 34 20
Satisfied with labour pain relief 1.00 (0.97 to 1.03)
Strongly agree 791 (67.2) 774 (67.4)
Agree 300 (25.5) 288 (25.1)
Neutral 60 (5.1) 51 (4.4)
Disagree 14 (1.2) 23 (2.0)
Strongly disagree 12 (1.0) 13 (1.1)
Missing 31 16
a Unadjusted RRs presented as adjusted models did not converge.
b Strongly agree/agree vs. strongly disagree/disagree/neutral.
Reproduced from The Epidural and Position Trial Collaborative Group.39 This is an Open Access article distributed
in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.
See: http://creativecommons.org/licenses/by/4.0/.
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TABLE 10 Infant outcomes
Outcome
Trial arm
Adjusteda effect measure
(99% CI)
Upright
(N= 1556)
Lying down
(N= 1537)
Apgar score of < 4 at 5 minutes, n (%) 2 (0.1) 3 (0.2) RR 0.66 (0.06 to 6.88)
Missing 5 7
Metabolic acidosis,b n (%) 6 (0.4) 17 (1.2) RR 0.35 (0.10 to 1.18)
pH and/or base deficit not donec 531 (35.5) 597 (40.4)
Missing 61 60
Meconium-stained liquor at delivery, n (%) 347 (22.4) 341 (22.2) RR 1.01 (0.85 to 1.19)
Missing 6 4
Resuscitation at birth, n (%) 206 (13.3) 180 (11.7) RR 1.13 (0.89 to 1.45)
Missing 1 2
Methodd
Facial oxygen 122 (59.5) 94 (52.2)
Suction 75 (36.6) 74 (41.1)
Bag and mask ventilation 82 (40.0) 82 (45.6)
Intubation 6 (2.9) 8 (4.4)
Complex resuscitation 4 (2.0) 1 (0.6)
Missing 1 0
Skin-to-skin contact in first hour after birth, n (%) 1165 (77.1) 1163 (78.4) RR 0.98 (0.94 to 1.03)e
Missing 45 53
Breastfeeding initiated in first hour after birth, n (%) 780 (51.3) 781 (52.1) RR 0.98 (0.90 to 1.07)
Missing 36 38
Length of inpatient hospital stay (hours) from birth
Median (IQR) 38.7 (24.8–59.7) 37.5 (24.2–56.9) Median differencef –1.1
(–3.1 to 0.8)
Missing 51 38
Admission to HLC,g n (%) 108 (7.0) 96 (6.3) RR 1.11 (0.79 to 1.56)
Missing 1 1
Length of stay in HLCh (days)
Total 71 63
Median (IQR) 2 (1–4) 3 (1–6) Median differencef 1 (0 to 2)
Missing 4 5
IQR, interquartile range.
a Adjusted for centre.
b Defined as cord-artery pH of < 7.05 with base deficit of ≥ 12 mmol/l.
c Included in denominator.
d Categories are not mutually exclusive.
e Unadjusted model presented as adjusted model did not converge.
f Not adjusted for centre.
g Includes transitional care.
h Excludes transitional care.
Reproduced from The Epidural and Position Trial Collaborative Group.39 This is an Open Access article distributed
in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.
See: http://creativecommons.org/licenses/by/4.0/.
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the lying-down group than in the upright group, but this difference was not statistically significant at the
1% level. Of interest, of the 23 babies with metabolic acidosis, 10 (six in the lying-down group and four
in the upright group) were born in apparently normal condition with normal Apgar scores and with no
evidence that they required resuscitation at the time of birth. Only eight of these babies received any HLC
(six in the lying-down group and two in the upright group).
Overall, about 12% of babies required resuscitation at birth. This figure was slightly higher in the upright
group than in the lying-down group, but this difference was not statistically significant at the 1% level.
There was also a suggestion that babies in the upright group may have required more intensive
resuscitation at birth, but again the numbers were very small and this difference was not statistically
significant. There was no evidence of a difference in the proportions of babies with skin-to-skin contact in
the first hour after birth, or in the proportions of babies who were breastfed in the first hour after birth.
Median length of stay in hospital was approximately 38 hours for each group, and approximately 7% of
babies were admitted for HLC (which included transitional care, special care or intensive care).
The data on adherence to the intervention are presented in Table 11 and Figure 9.
The prespecified subgroup analyses are presented as forest plots in Figure 10 and Table 12. There is no
evidence of heterogeneity between any of the prespecified subgroups for the primary outcome of SVB.
TABLE 11 Adherence (proportion of time spent in allocated position)
Outcome
Trial arm
Median difference
(95% CI)
Upright
(n= 1556)
Lying down
(n= 1537)
During the passive second stage,a median (IQR) 1.0 (1.0–1.0) 1.0 (0.67–1.0) 0 (0 to 0)
Missing: no passive time periods recorded 320 314
Missing: time from study entry to start of recording
positions at > 15 minutes
227 217
Missing: pushing or birth dates/times not recorded 13 10
Missing: position times not recorded 50 36
During the active second stage,b median (IQR) 0.88 (0.60–1.0) 0.75 (0.38–1.0) 0 (0 to 0)
Missing: no active time periods recorded 11 19
Missing: time from study entry to start of recording
positions at > 15 minutes
227 217
Missing: pushing or birth dates/times not recorded 13 10
Missing: position times not recorded 50 36
During the whole second stage,c median (IQR) 0.88 (0.67–1.0) 0.78 (0.50–1.0) 0 (0–0)
Missing: time from study entry to start of recording
positions at > 15 minutes
227 217
Missing: birth dates/times not recorded 1 0
Missing: position times not recorded 54 36
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TABLE 11 Adherence (proportion of time spent in allocated position) (continued )
Outcome
Trial arm
Median difference
(95% CI)
Upright
(n= 1556)
Lying down
(n= 1537)
Reason for change from allocated position, n (%)
Passive stage 201 343 –
Clinical 94 (50.0) 78 (24.5)
Non-clinical 77 (41.1) 218 (68.3)
Clinical and non-clinical 17 (9.0) 23 (7.2)
Missing 13 24
Active stage 699 981
Clinical 416 (60.6) 298 (31.1)
Non-clinical 136 (19.8) 368 (38.5)
Clinical and non-clinical 135 (19.7) 291 (30.4)
Missing 12 24
Whole of second stage 788 1082
Clinical 435 (56.6) 306 (28.9)
Non-clinical 164 (21.3) 419 (39.5)
Clinical and non-clinical 170 (22.1) 335 (31.6)
Missing 19 22
Maternal reported adherence, n (%)
Passive stage
Mostly lying down 226 (21.6) 752 (72.3)
Mostly upright 794 (75.8) 242 (23.3)
Other 24 (2.3) 35 (3.4)
Cannot remember 3 (0.3) 11 (1.1)
Missing 161 125
Form not completed 348 372
Active stage
Mostly lying down 202 (19.7) 652 (63.7)
Mostly upright 745 (72.5) 281 (27.4)
Other 78 (7.6) 75 (7.3)
Cannot remember 3 (0.3) 16 (1.6)
Missing 180 141
Form not completed 348 372
a Defined as the time from study entry to when pushing commenced.
b Defined as the time from when pushing commenced until birth.
c Defined as the time from study entry until birth.
Adapted from The Epidural and Position Trial Collaborative Group.39 This is an Open Access article distributed in accordance
with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt
and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/
licenses/by/4.0/.
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FIGURE 9 Box and whisker plots of adherence (proportion of time spent in allocated position). (a) Passive stage;
(b) active stage; and (c) whole of second stage. Reproduced from The Epidural and Position Trial Collaborative
Group.39 This is an Open Access article distributed in accordance with the terms of the Creative Commons
Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
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0.60 0.77 1.00 1.29 1.67
Adjusteda RR
(95% CI)
Interaction
p-value Number of events/total number (%)
Upright Lying down
Favours lying down Favours upright
Gestational age (weeks)
37+0 to 38+6 0.85 (0.67 to 1.07)76/198 (38.4) 97/211 (46.0)
39+0 to 40+6 0.84 (0.74 to 0.95)278/774 (35.9) 320/745 (43.0)
≥ 41+0 0.89 (0.76 to 1.04)
0.84
193/581 (33.2) 215/580 (37.1)
Maternal age (years)
< 25 0.89 (0.78 to 1.02)199/414 (48.1) 210/391 (53.7)
25–29 0.87 (0.74 to 1.03)155/437 (35.5) 188/463 (40.6)
30–34 0.79 (0.66 to 0.94)141/488 (28.9) 178/482 (36.9)
≥ 35 0.88 (0.64 to 1.21)
0.75
53/216 (24.5) 56/201 (27.9)
Oxytocin in first stageb
Yes 0.82 (0.71 to 0.95)221/683 (32.4) 255/649 (39.3)
No 0.89 (0.79 to 0.99)
0.42
327/872 (37.5) 376/885 (42.5)
IMD: quintile 
First (least deprived) 0.81 (0.61 to 1.07)59/205 (28.8) 74/204 (36.3)
Second 0.96 (0.74 to 1.26)66/182 (36.3) 76/201 (37.8)
Third 0.78 (0.61 to 0.99)78/246 (31.7) 96/235 (40.9)
Fourth 0.72 (0.60 to 0.87)113/349 (32.4) 155/345 (44.9)
Fifth (most deprived) 0.97 (0.81 to 1.15)
0.19
135/299 (45.2) 134/294 (45.6)
FIGURE 10 Subgroup analyses for SVB (forest plot). a, All models adjusted for centre as a random effect; and b, diagnosis of delay prior to study entry requiring oxytocin.
Reproduced from The Epidural and Position Trial Collaborative Group.39 This is an Open Access article distributed in accordance with the terms of the Creative Commons
Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.
See: http://creativecommons.org/licenses/by/4.0/.
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Responses to postal questionnaires at 1 year after the birth were received from 61% of women. The
characteristics of women who did and did not respond to the questionnaire are detailed in Table 13.
Responders were more likely to be slightly older and live in less deprived areas, and to be white. They were
also less likely to have had a SVB, and more likely to have had an instrumental delivery. There were no
differences between responders and non-responders in the risk of caesarean section or the onset of labour
(spontaneous or induced), or in the incidence of neonatal resuscitation or for their babies to be admitted
to a HLC.
Table 14 list the secondary maternal outcomes up to 1 year after birth in women who responded to the
questionnaires. There was no evidence of any differences between the groups in relation to the incidence
or severity of urinary incontinence, faecal incontinence, constipation, haemorrhoids or dyspareunia.
Similarly, there was no evidence of a difference in the incidence of diagnosed cerebral palsy or severe
neurodevelopmental delay in any of the infants at 1 year (see Table 15).
The prespecified sensitivity analysis, which excluded women who had another birth or were pregnant at
the time of the 1-year follow-up, demonstrates no change in the conclusions of the study (see Table 16).
There were a number of adverse events reported during the course of the trial. The majority of these did
not appear to be related to the intervention (Table 17).
TABLE 12 Subgroup analyses for SVB
Factor
Trial arm
Adjusteda RR
(95% CI)
Interaction
p-value
Upright
(N= 1556), n (%)
Lying down
(N= 1537), n (%)
Gestational age (weeks)
37+0 to 38+6 76/198 (38.4) 97/211 (46.0) 0.85 (0.67 to 1.07) 0.839
39+0 to 40+6 278/774 (35.9) 320/745 (43.0) 0.84 (0.74 to 0.95)
≥ 41+0 193/581 (33.2) 215/580 (37.1) 0.89 (0.76 to 1.04)
Maternal age (years)
< 25 199/414 (48.1) 210/391 (53.7) 0.89 (0.78 to 1.02) 0.747
25–29 155/437 (35.5) 188/463 (40.6) 0.87 (0.74 to 1.03)
30–34 141/488 (28.9) 178/482 (36.9) 0.79 (0.66 to 0.94)
≥ 35 53/216 (24.5) 56/201 (27.9) 0.88 (0.64 to 1.21)
Oxytocin in the first stageb
Yes 221/683 (32.4) 255/649 (39.3) 0.82 (0.71 to 0.95) 0.417
No 327/872 (37.5) 376/885 (42.5) 0.89 (0.79 to 0.99)
IMD: quintile
First (least deprived) 59/205 (28.8) 74/204 (36.3) 0.81 (0.61 to 1.07) 0.187
Second 66/182 (36.3) 76/201 (37.8) 0.96 (0.74 to 1.26)
Third 78/246 (31.7) 96/235 (40.9) 0.78 (0.61 to 0.99)
Fourth 113/349 (32.4) 155/345 (44.9) 0.72 (0.60 to 0.87)
Fifth (most deprived) 135/299 (45.2) 134/294 (45.6) 0.97 (0.81 to 1.15)
a All models adjusted for centre as a random effect.
b Diagnosis of delay prior to study entry requiring oxytocin.
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TABLE 13 Generalisability of women followed up
Characteristic
1-year follow-up
p-valueReceived (N= 1892) Not received (N= 1201)
Maternal age (years)
Mean (SD) 29.7 (5.2) 26.5 (5.7) p< 0.001a
Missing 0 1
Gestational age at entry (weeks)
Mean (SD) 40.4 (1.2) 40.3 (1.2) p= 0.048a
Missing 1 3
IMD: quintile, n (%) p< 0.001b
First (least deprived) 279 (17.6) 130 (13.3)
Second 259 (16.4) 124 (12.7)
Third 318 (20.1) 163 (16.7)
Fourth 431 (27.2) 263 (26.9)
Fifth (most deprived) 295 (18.7) 298 (30.5)
Wales: not derived 265 176
Postcode missing 45 47
Ethnic group, n (%) p< 0.001b
White 1624 (86.5) 956 (80.1)
Indian 58 (3.1) 47 (3.9)
Pakistani 22 (1.2) 34 (2.9)
Bangladeshi 3 (0.2) 6 (0.5)
Black African 30 (1.6) 28 (2.4)
Black Caribbean 11 (0.6) 14 (1.2)
Any other ethnic group 129 (6.9) 109 (9.1)
Not known/missing 15 7
BMI at booking visit (kg/m2)
Mean (SD) 25.2 (5.2) 25.6 (5.6) p= 0.030a
Height and/or weight not known, n 70 55
Onset of labour, n (%)
Spontaneous 1121 (59.3) 724 (60.3) p= 0.573b
Induced 769 (40.7) 476 (39.7)
Missing 2 1
Diagnosis of delay requiring
intervention, n (%)
985 (52.1) 581 (48.4) p= 0.043b
Missing 3 1
SVB, n (%) 677 (35.8) 503 (41.9) p= 0.001b
Missing 0 1
IVD,c n (%) 1040 (55.0) 587 (48.9) p= 0.001b
Missing 0 1
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TABLE 13 Generalisability of women followed up (continued )
Characteristic
1-year follow-up
p-valueReceived (N= 1892) Not received (N= 1201)
Caesarean section,d n (%) 175 (9.3) 110 (9.2) p= 0.94b
Missing 0 1
Episiotomy performed, n (%) 1120 (59.2) 632 (52.7) p< 0.001b
Missing 1 1
Obstetric anal sphincter injury,e n (%) 116 (6.1) 69 (5.8) p= 0.675b
Missing 2 5
Perineum sutured, n (%) 1585 (83.9) 947 (79.1) p= 0.001b
Missing 2 3
Resuscitation at birth, n (%) 241 (12.8) 145 (12.1) p= 0.584b
Missing 2 1
Breastfeeding initiated in the first hour
after birth, n (%)
994 (53.8) 567 (48.4) p= 0.004b
Missing 45 29
Infant admission to HLC,f n (%) 121 (6.4) 83 (6.9) p= 0.572b
Missing 1 1
a t-test preformed.
b Chi-squared test performed.
c Compared with no IVD.
d Compared with no caesarean section.
e Severity grades 3 and 4.
f Includes transitional care.
Adapted from The Epidural and Position Trial Collaborative Group.39 This is an Open Access article distributed in accordance
with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt
and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/
licenses/by/4.0/.
TABLE 14 Secondary maternal outcomes up to 1 year
Outcome
Trial arm
Adjusteda effect measure
(99% CI)Upright (N= 950) Lying down (N= 942)
Urinary incontinence, n (%)
Leaking in the first 3 months 462 (48.8) 461 (49.2) RR 0.99 (0.88 to 1.12)
Missing 4 4
ICIQ-UI scoreb over the past 4 weeks
Median (IQR) 0 (0–4) 0 (0–4) Median differencef 0 (0 to 0)
Missing, n 39 34
Faecal incontinence, n (%)
No bowel control and/or soiling
In the first 3 months 108 (11.5) 132 (14.2) RR 0.81 (0.59 to 1.11)
Missing 7 9
In the past 4 weeks 32 (3.4) 27 (2.9) RR 1.18 (0.61 to 2.28)
Missing 10 8
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TABLE 14 Secondary maternal outcomes up to 1 year (continued )
Outcome
Trial arm
Adjusteda effect measure
(99% CI)Upright (N= 950) Lying down (N= 942)
No bowel control and/or soiling and/or feel need to go, n (%)
In the first 3 months 215 (22.8) 251 (26.9) RR 0.85 (0.69 to 1.05)
Missing 8 8
In the past 4 weeks 113 (12.1) 102 (10.9) RR 1.10 (0.79 to 1.53)
Missing 12 10
No bowel control at times,c n (%)
Never 829 (87.9) 806 (86.1)
In the first 3 months 83 (8.8) 103 (11.0)
In the past 4 weeks 13 (1.4) 19 (2.0)
At any other time 29 (3.1) 20 (2.1)
Missing 7 5
Soiling from back passage on underwear,c n (%)
Never 836 (88.6) 838 (89.5)
In the first 3 months 70 (7.4) 75 (8.0)
In the past 4 weeks 24 (2.5) 14 (1.5)
At any other time 24 (2.5) 22 (2.4)
Missing 6 6
Feel need to go and have to go immediately,c n (%)
Never 640 (67.9) 616 (65.8) RR 0.85 (0.67 to 1.08)
In the first 3 months 173 (18.4) 202 (21.6)
In the past 4 weeks 98 (10.4) 90 (9.6) RR 1.08 (0.76 to 1.55)
At any other time 77 (8.2) 82 (8.8)
Missing 8 6
Constipation,c n (%)
Never 367 (38.9) 406 (43.2) RR 1.12 (0.96 to 1.29)
In the first 3 months 395 (41.8) 353 (37.6)
In the past 4 weeks 94 (10.0) 107 (11.4) RR 0.87 (0.62 to 1.23)
At any other time 140 (14.8) 154 (16.4)
Missing 6 2
Haemorrhoids,c n (%)
Never 495 (52.4) 518 (55.1) RR 1.03 (0.87 to 1.23)
In the first 3 months 308 (32.6) 297 (31.6)
In the past 4 weeks 108 (11.4) 116 (12.3) RR 0.93 (0.67 to 1.28)
At any other time 108 (11.4) 115 (12.2)
Missing 6 2
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TABLE 14 Secondary maternal outcomes up to 1 year (continued )
Outcome
Trial arm
Adjusteda effect measure
(99% CI)Upright (N= 950) Lying down (N= 942)
Dyspareunia,c,d n (%)
Never 366 (40.7) 363 (40.6) RR 0.95 (0.82 to 1.10)
In the first 3 months 364 (40.5) 381 (42.6)
In the past 4 weeks 80 (8.9) 79 (8.8) RR 1.01 (0.68 to 1.49)
At any other time 160 (17.8) 151 (16.9)
Missing 5 2
Not applicable (not had sexual
intercourse since the birth)
46 45
ICIQ-UI, International Consultation on Continence Modular Questionnaire – Urinary Incontinence; IQR, interquartile range.
a Adjusted for centre.
b Scored on a scale of 0 to 21, with a high score indicating worse problems.
c Woman could tick more than one option, so percentages may total > 100%.
d Excludes women who have not had sexual intercourse.
Adapted from The Epidural and Position Trial Collaborative Group.39 This is an Open Access article distributed in accordance
with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt
and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/
licenses/by/4.0/.
TABLE 15 One-year infant outcomes
Outcome
Trial arm
Adjusteda RR (99% CI)
Upright (N= 950),
n (%)
Lying down (N= 942),
n (%)
Major morbidityb 1 (0.11) 4 (0.42) 0.25 (0.01 to 4.40)
a Adjusted for centre.
b For example gross neurodevelopmental delay, including cerebral palsy (if a diagnosis has been made).
TABLE 16 Sensitivity analysis: 1-year maternal outcomes, excluding women who had another child/were pregnant
at the time of assessment
Outcome
Trial arm
Adjusteda effect measure
(99% CI)Upright (N= 950) Lying down (N= 942)
Women who have had another baby,
n (%)
6 (0.6) 4 (0.4)
Missing 6 14
Women pregnant at time of
completing questionnaire, n (%)
61 (6.5) 72 (7.8)
Missing 9 20
Denominator excluding women who
were pregnant/had another baby
883 866
Urinary incontinence, n (%)
Leaking in the first 3 months 432 (49.2) 426 (49.4) RR 0.99 (0.88 to 1.13)
Missing 4 4
RESULTS
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TABLE 16 Sensitivity analysis: 1-year maternal outcomes, excluding women who had another child/were pregnant
at the time of assessment (continued )
Outcome
Trial arm
Adjusteda effect measure
(99% CI)Upright (N= 950) Lying down (N= 942)
ICIQ-UI scoreb over the past 4 weeks
Median (IQR) 0 (0–4) 0 (0–4) Median difference 0 (0 to 0)
Missing 38 30
Faecal incontinence
No bowel control and/or soiling
In the first 3 months 101 (11.5) 122 (14.2) RR 0.81 (0.59 to 1.12)
Missing 7 9
In the past 4 weeks 28 (3.2) 27 (3.2) RR 1.02 (0.51 to 2.02)
Missing 10 8
No bowel control and/or soiling and/or feel the need to go
In the first 3 months 203 (23.2) 235 (27.4) RR 0.85 (0.68 to 1.05)
Missing 8 7
In the past 4 weeks 106 (12.2) 93 (10.9) RR 1.12 (0.79 to 1.58)
Missing 12 9
Feel need to go and have to go immediatelyc
In the first 3 months 161 (18.4) 191 (22.2) RR 0.83 (0.65 to 1.06)
In the past 4 weeks 92 (10.5) 81 (9.4) RR 1.12 (0.77 to 1.62)
Missing 8 5
Constipation,c n (%)
In the first 3 months 368 (42.0) 328 (38.0) RR 1.11 (0.95 to 1.29)
In the past 4 weeks 82 (9.4) 90 (10.4) RR 0.90 (0.62 to 1.30)
Missing 6 2
Haemorrhoids,c n (%)
In the first 3 months 291 (33.2) 278 (32.2) RR 1.03 (0.86 to 1.23)
In the past 4 weeks 100 (11.4) 102 (11.8) RR 0.97 (0.69 to 1.36)
Missing 6 2
Dyspareunia,c,d n (%)
In the first 3 months 339 (40.7) 351 (42.9) RR 0.95 (0.82 to 1.10)
In the past 4 weeks 75 (9.0) 78 (9.5) RR 0.95 (0.64 to 1.41)
Missing 5 2
Not applicable (not had sexual
intercourse since the birth)
45 45
ICIQ-UI, International Consultation on Continence Modular Questionnaire – Urinary Incontinence; IQR, interquartile range.
a Adjusted for centre.
b Scored on a scale of 0 to 21, a high score indicating worse problems.
c Woman could tick more than one option so percentages may total.
d Excludes women who have not had sexual intercourse.
Adapted from The Epidural and Position Trial Collaborative Group.39 This is an Open Access article distributed in accordance
with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt
and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/
licenses/by/4.0/.
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TABLE 17 Adverse events
Adverse event
Trial arm
Upright (N= 1556) Lying down (N= 1537)
Woman, n
Dizziness 29 21
Post-partum haemorrhage 1 1
Seizure 0 2
Other 3 3
Baby, n
Stillbirth 1 0
Birth trauma 1 0
Other 2 0
RESULTS
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Chapter 6 Economic evaluation
In this chapter we present the results of the economic evaluation conducted alongside the BUMPES trial.A within-trial cost–consequences analysis with a time horizon of a 1-year follow-up and a NHS perspective
was conducted. The aim of this analysis was to inform about health-care utilisation and costs for the treatment
pathways followed by mothers and their babies from trial entry up to 1 year after birth. In addition to the
consequences of the different positions during the late stages of labour in women with an epidural presented
in previous chapters, we also report maternal health-related quality of life (HRQoL) at 1 year after birth.
Details of each component of the economic analysis are provided in this chapter.
Methods
A health economics analysis plan was developed to guide the health economics team during the
development of the economic evaluation (see Appendix 8). Overall, the team followed this analysis plan
during the conduct of the economic evaluation, but there was one deviation from the plan that affected
the final presentation of results of the economic analysis. The original analysis plan stated quality-adjusted
life-years (QALYs) as the primary health outcome measure and used a cost–utility analysis to present the
results of the economic evaluation. However, quality-of-life data at randomisation were not collected owing
to the intrinsic difficulties in collecting this information during labour. In addition, it was not planned to
collect data during the early postnatal period as part of the trial. As a result, the calculation of a QALY
profile for the trial duration could not be derived. The next alternative could have been to conduct a
cost-effectiveness analysis using the primary outcome in the trial or another clinical end point to present
the results of the economic analysis. However, given that this was, to our knowledge, the first economic
evaluation of position during labour, the results of such an analysis would have been difficult to interpret by
decision-makers in the absence of a willingness to pay for health gains for the selected outcome. Therefore,
we decided to conduct a cost–consequences evaluation as the primary analysis for the economic evaluation.
In a cost–consequences analysis, the different components of costs and benefits of the interventions under
evaluation are presented in a disaggregated manner without an attempt to estimate a summary measure
[e.g. incremental cost-effectiveness ratio (ICER)].41 As a secondary outcome of the economic analysis we
conducted a cost-effectiveness analysis using the number of additional cases of SVB as the outcome
measure. The latter analysis was included as a benchmark for future economic evaluations studies
in obstetrics.
Health outcome measures
Health outcomes for women and their babies before discharge and at the 1-year follow-up were evaluated
as potential consequences to include in the economic evaluation. Chapter 5 reported a number of secondary
maternal, neonatal and longer-term outcomes in addition to the primary outcome in the trial. Most of these
outcomes led to health-care service utilisation, which was accounted for in our analysis, and only a selection
of maternal and infant outcomes were therefore included in the cost–consequences analysis. For women,
we selected the incidence of SVB, maternal satisfaction with labour as reported immediately after the birth
and urinary and faecal incontinence at 1 year’s follow-up. An Apgar score of < 4 at 5 minutes and major
morbidity at 1 year’s follow-up were the consequences selected for infants. When reporting the results of
difference in estimates between upright and lying-down positions for any of these outcomes, we refer to the
appropriate tables in Chapter 5 rather than replicating the tables here.
In addition to the above consequences, maternal HRQoL information using the EuroQol-5 Dimensions,
three-level version (EQ-5D-3L) and the Short Form questionnaire-12 items (SF-12) instruments was collected
at the 1-year follow-up. The EQ-5D-3L is an increasingly widely used multiattribute generic instrument for
measuring HRQoL in cost–utility analyses.42 It has two components: a descriptive system covering five
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dimensions (mobility, self-care, usual activity, pain/discomfort and anxiety/depression), each of which
has three levels (no problem, some problems and extreme problems), and a ‘feeling thermometer’ using a
visual analogue scale. The 243 health states of the EQ-5D-3L can be converted into preference-based utility
values using a value set obtained from a British general population sample.43 The SF-12 is a generic HRQoL
instrument derived from its longer counterpart, the Short Form questionnaire-36 items (SF-36),44 designed to
measure general health functioning. The SF-12 items measure physical or emotional limitations, physical
functioning, pain, general health, vitality, social functioning and mental health problems. The number of
levels in each SF-12 question varies depending on the version used, and in this study the SF-12 version 2
was administered. Health states from the SF-12 instrument can be converted into preference-based utilities
using the Short Form questionnaire-6 Dimensions (SF-6D) algorithm, which was used in this study.45
NHS health-care resource use
Detailed information about secondary care usage was collected and included resources consumed during
the late stages of labour to hospital discharge, and during the first 12 months after birth as reported at the
1-year follow-up. Chapter 5 reported some data about health-care usage that we also present in this
chapter with additional information. Data from trial entry up to postnatal hospital discharge were collected
from hospital records and included in the DCB (see Appendix 1). A postal questionnaire was used to
collect secondary care information at the 1-year follow-up, and this was sent by the trial management
team, which also dealt with reminders and appropriate double-data entry and data cleaning. Information
was collected for women and their babies. The different items of resource use collected for each category
of secondary care health service are summarised in Table 18.
No intervention-specific costs were assigned to either upright or lying-down position as neither was
associated with the use of any additional resources . Given that all randomised women already had epidural
analgesia and that any remaining medication after the birth was considered to be waste, epidural-specific
costs were excluded from the cost analysis. In addition, any top-up epidural drugs costs in both arms were
excluded from the cost analysis as there was no evidence of a difference between groups (see Table 7).
TABLE 18 Categories of resource use and associated unit costs used in the cost analysis (expressed in 2013/14 UK £)
Resource use item
Unit
cost (£) Source Notes
Maternal
Birth related
Augmentation (oxytocin) 1 BNF 201546 Oxytocin, injection, price for
10 units/ml, 1-ml ampoule
Fetal blood sampling 28 John Radcliffe Hospital Women’s
Centre (Oxford)
Obtained from hospital finance
department
Fetal scalp electrode 5 Schroeder et al.47
Hypotension medication 10 BNF 201546 Injection, phenylephrine
hydrochloride 10 mg/ml (1%),
1-ml ampoule = £9.91
Mode of birth
Vaginal delivery 1462 NHS Reference Costs 2013–1448 Normal delivery with a complication
score of 0 (HRG data)
Assisted delivery 1860 NHS Reference Costs 2013–1448 Assisted delivery with a complication
score of 0 (HRG data)
Caesarean section delivery 3674 NHS Reference Costs 2013–1448 Emergency caesarean section
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TABLE 18 Categories of resource use and associated unit costs used in the cost analysis (expressed in 2013/14 UK £)
(continued )
Resource use item
Unit
cost (£) Source Notes
Episiotomy 27 Schroeder et al.47
Perineal tear
First- and second-degree tears 23 Schroeder et al.47
Third- and fourth-degree tears 64 Schroeder et al.47
Manual removal of the placenta 74 Schroeder et al.47
Post-partum haemorrhage 154 Eddama et al.49
Blood transfusion 157 Schroeder et al.47 Per blood pack
HLC admissions
Level of care (per day)
Level 0 643 NHS Reference Costs 2013–1448
Level 1 890 NHS Reference Costs 2013–1448
Level 2 1266 NHS Reference Costs 2013–1448
Level 3 1449 NHS Reference Costs 2013–1448
Investigations
MRI 139 NHS Reference Costs 2013–1448
CT 80 NHS Reference Costs 2013–1448
Radiography 48 NHS Reference Costs 2013–1448
Transfer to another hospital 435 Schroeder et al.47
Outpatient visits
Perineal care clinic 13 NHS Reference Costs 2013–1448
Gynaecological 13 NHS Reference Costs 2013–1448
Surgical 11 NHS Reference Costs 2013–1448
Other 127 – Average cost of outpatient visits
Hospital visits
Hospital inpatient (per day) 757 NHS Reference Costs 2013–1448 Average cost of regular day or
night admissions
Postnatal ward stay (per day) 103 Schroeder et al.47
Infant
Birth related
Cord blood sampling 0.05 Schroeder et al.47
HLC admissions
Level of care (per day)
Special care 41 NHS Reference Costs 2013–1448
High dependency 839 NHS Reference Costs 2013–1448
Intensive care 1118 NHS Reference Costs 2013–1448
continued
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At the study design stage, there was a general concern about including primary care and community care
visits as part of the data collection because these tend to be frequent and poorly recalled by new mothers
compared with secondary care visits.50 It was agreed that hospital care constituted the main cost driver for this
population and the target source data to collect in the study. Therefore, primary care and community care
visit data were not collected. However, urinary and faecal incontinence are important outcomes following
birth and may be related to the mode of delivery, and can have long-lasting effects on HRQoL and additional
visits to primary care.17,21 Therefore, it was decided that, if necessary, primary care visits related to these
adverse events would be estimated using recent data from the literature if significant differences between
treatment arms were observed. Nevertheless, this was not the case (see Table 14), and such visits were not
incorporated as part of the categories of resource use in the cost analysis and are presented as part of the
health outcomes in the cost–consequences analysis. We also assumed that any costs for specific surgeries
were reflected in the length of stay and the unit cost attached to the admission. Therefore, we did not
conduct a micro-costing approach for the maternal and infant surgeries performed in different time periods.
Unit cost data collection
Sources and associated estimates of unit costs for the different categories of resource use are presented in
Table 18. Unit costs were mainly extracted from national sources, including the Personal Social Services
Research Unit51 and the NHS Reference Costs 2013–14,48 and from a recent published cost-effectiveness
analysis of alternative planned places of birth in woman at low risk of complications.47 The unit cost of
undertaking fetal blood sampling for the assessment of metabolic acidosis was not available in any of the
sources consulted and was provided by the finance department of a large obstetric unit in Oxford. All costs
were expressed in 2013/14 pounds sterling inflated to this base using the Hospital and Community Health
Service Inflation Index52 where appropriate.
TABLE 18 Categories of resource use and associated unit costs used in the cost analysis (expressed in 2013/14 UK £)
(continued )
Resource use item
Unit
cost (£) Source Notes
Investigations
Radiography 85 NHS Reference Costs 2013–1448
CT scans 37 NHS Reference Costs 2013–1448
MRI 48 NHS Reference Costs 2013–1448
Transfer to another hospital 1259 NHS Reference Costs 2013–1448 Neonatal critical care,
transportation
Neonatal death 696 Schroeder et al.47
Outpatient visits
Orthopaedic 148 NHS Reference Costs 2013–1448
Paediatric 289 NHS Reference Costs 2013–1448
Hearing 138 NHS Reference Costs 2013–1448
Eye 115 NHS Reference Costs 2013–1448
Dermatology 144 NHS Reference Costs 2013–1448
Other 167 – Average cost of outpatient
Hospital visits
Hospital inpatient (per day) 886 NHS Reference Costs 2013–1448 Paediatric high-dependency ward
CT, computerised tomography; HRG, Healthcare Resource Group; MRI, magnetic resonance imaging.
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Statistical analysis
Volumes of categories of resource use were multiplied by the corresponding unit cost to estimate the cost
per woman or baby in a particular category. This was then averaged across each trial arm to obtain a
mean cost per woman or baby of a particular category. We estimated health-care resource use deriving
mean estimates and SDs either across all women and their babies in an arm of the trial or only for those
consuming the resource category. The latter analysis using standard descriptive statistics was expected to
provide information about potential outliers influencing the estimation of mean resource use and costs for
a particular category of resource use in each arm of the trial. Categories of resource use and associated
costs are presented separately for women and their babies, but the estimation of summary costs for a
particular resource use category (e.g. total costs at 12-month follow-up) was calculated adding information
from the pair. Health-care resource use between treatment arms was compared using RRs for binomial
variables and mean differences for continuous covariates. Costs were compared using mean differences
between treatment arms. Recent evidence suggests that both parametric and non-parametric methods
accurately estimate the true standard errors (SEs) of means, even when data are highly skewed, and
moderate to large (n > 50) sample sizes for continuous variables.53 Hence, mean resource use and cost
differences and associated uncertainty for particular categories of resource use and costs between the two
positions during the late stage of labour were estimated using parametric methods. In line with the
statistical analysis of the primary outcome, differences between treatment arms were adjusted using a
random intercept binomial (for RRs) or linear (for mean differences) model using hospital centre as a
random effect. In order to be consistent with the original SAP, a 95% significance level was defined to
determine significant differences in health-care resource use for the primary outcome (SVB) whereas a
99% significance level was used for the other categories of resource use. A 95% significance level was
used to compare main categories of costs between treatment arms.
Mean differences and associated uncertainty in EQ-5D-3L and SF-6D utilities between the treatment arms were
assessed using parametric methods and adjusted using a random intercept linear model for hospital centre.
The number of missing data for secondary care resource use up to hospital discharge was very low in each
treatment arm (< 1%), and we present the health-care resource use and costs during this period using a
complete-case analysis. The proportion of missing data on both resource use and HRQoL was higher at the
1-year follow-up. In this case, resource use was presented using a complete-case analysis, but in the case of
maternal quality-of-life scores and costs we implemented a multiple imputation framework with chained
equation.54 Current guidance on handling missing data in cost-effectiveness analysis was followed to inform
such analysis.55 Only missing utility scores (for both EQ-5D-3L index and SF-6D utilities) and individual cost
items were imputed and the distribution of responses for both instruments was reported for data available.
We constructed an imputation model that included covariates with complete data on trial entry characteristics
(maternal age, gestational age at entry, BMI and baby’s birth weight), HRQoL variables (EQ-5D-3L and SF-6D
scores), and all individual categories of cost variables. We used prediction mean-matching, estimated 50
different imputations, and the imputation model was implemented separately by trial allocation. Mean
estimates and estimates of SE were combined between imputed data sets using Rubin’s rule56 and adjusted
using a random intercept linear model for hospital centre.
Mean differences in the total costs at 12 months’ follow-up and the number of additional cases of SVB
between treatment arms were combined into the ICER to determine cost-effectiveness as a secondary
outcome in the economic evaluation. The lying-down position was used as the comparator in the ICER
calculation. Uncertainty around the ICER was evaluated parametrically using 95% CIs.57 The five parameters
needed (difference in costs, SE of difference in costs, difference in effects, SE of difference in effects and
correlations of differences in costs and effects) to estimate parametrically the uncertainty around the ICER
were obtained from the multiple imputation analysis.
The statistical analysis was conducted in Stata/SE for Windows version 13.1.
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Results
Clinical consequences
In Chapter 5 we reported that there were significantly fewer SVBs in the upright group (see Table 5) and
that we found no evidence of differences between the two intervention groups in maternal satisfaction
(see Table 9), maternal urinary and faecal incontinence (see Table 14), frequency of Apgar score of < 4 at
5 minutes (see Table 10) or major morbidity (see Table 15).
NHS health-care resource use
Tables 19 and 20 present the maternal and infant health-care resource use from trial entry to postnatal
hospital discharge for the birth-related, HLC admissions and hospital length of stay categories of resource
use. In line with reporting of the primary outcome in Chapter 5, the only statistically significant difference
observed between trial arms was the higher number of SVBs in the lying-down arm. The number of infants
in whom cord blood was sampled was slightly higher in the upright group than in the lying-down group,
yielding a statistically significant RR (99% CI) of 1.012 (1.010 to 1.013). No other significant differences
were detected.
TABLE 19 Maternal health-care resource use from trial entry to hospital discharge
Health-care resource use
Trial arm
RR/MD (99% CI)a
Upright
(N= 1556)
Lying down
(N= 1537)
Delivery-related, n (%)
Augmentation (oxytocin) 172 (11.08) 163 (10.62) 1.04 (0.80 to 1.35)
Missing 3 2
Fetal blood sampling 90 (5.80) 72 (4.69) 1.17 (0.82 to 1.68)
Missing 4 3
Fetal scalp electrode 94 (6.06) 85 (5.57) 1.09 (0.76 to 1.57)
Missing 6 11
Hypotension medication 13 (0.84) 12 (0.78) 1.07 (0.39 to 2.99)
Missing 3 2
Mode of birth
SVB 548 (35.24) 632 (41.12) 0.86 (0.78 to 0.94)*
IVD 849 (54.60) 778 (50.62) 1.08 (0.98 to 1.18)
Caesarean section 158 (10.16) 127 (8.26) 1.23 (0.92 to 1.64)
Missing 1 0
Episiotomy 914 (58.78) 838 (54.56) 1.08 (0.99 to 1.16)
Missing 1 1
Perineal tear 760 (48.97) 785 (51.11) 0.95 (0.87 to 1.04)
First- or second-degree tear 654 (42.19) 704 (45.83)
Third- or fourth-degree tear 104 (6.71) 81 (5.27)
Missing 6 1
Manual removal of the placenta 99 (6.48) 101 (6.72) 0.97 (0.69 to 1.38)
Missing 28 35
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A breakdown of health-care resources consumed at 12-month follow-up for women and their babies for
outpatient and hospital visits is presented in Table 21 using a complete-case analysis. No significant
differences for any of the categories between treatment groups were observed.
Similar information to that in Tables 19–20 is presented in Tables 22 and 23, but only for women and their
babies consuming the health-care resource use. The results from such analysis confirmed the presence of a
few individuals (as indicated by the range) consuming more of some resource use categories than the
remaining participants (e.g. one infant admitted for intensive care for 31 days in the upright position or
women having more than 30 visits as an outpatient in both groups). However, the impact of these outliers
was minimal when averaging across all participants, given the low number of participants consuming any
of these resources.
TABLE 19 Maternal health-care resource use from trial entry to hospital discharge (continued )
Health-care resource use
Trial arm
RR/MD (99% CI)a
Upright
(N= 1556)
Lying down
(N= 1537)
Post-partum haemorrhage with blood
transfusion
63 (4.05) 52 (3.39) 1.20 (0.75 to 1.92)
Missing 1 1
HLC admissions
Level of care (days), mean (SD)
Level 0 0.035 (0.339) 0.025 (0.320) 0.010 (–0.020 to 0.040)
Level 1 0.041 (0.222) 0.029 (0.201) 0.011 (–0.007 to 0.031)
Level 2 0.021 (0.202) 0.023 (0.191) –0.002 (–0.020 to 0.016)
Level 3 0.005 (0.076) 0.001 (0.036) 0.003 (–0.002 to 0.009)
Missing 3 2
Surgery performed 7 (0.45) 4 (0.26)
Missing 3 2
Transfer to another hospital 2 (0.13) 0 (0.00)
Missing 3 2
Investigations, mean (SD)
Radiography 0.0032 (0.0671) 0.0039 (0.0721) –0.0007 (–0.007 to 0.006)
CT 0.0013 (0.0359) 0.0007 (0.0255) 0.0006 (–0.002 to 0.005)
MRI 0 (0) 0.0007 (0.0255) –0.0007 (–0.002 to 0.001)
Missing 3 2
Hospital length of stay, mean (SD)
Length of stay (days) 2.73 (2.28) 2.74 (2.94) –0.003 (–0.242 to 0.243)
Missing 5 5
*p < 0.05.
CT, computerised tomography; MD, mean difference; MRI, magnetic resonance imaging.
a Adjusted for centre. 95% CI used for primary outcome (SVB).
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TABLE 20 Infant health-care resource use from trial entry to hospital discharge [values represent frequencies
(percentages) unless stated otherwise]
Health-care resource use
Trial arm
RR/MD (99% CI)aUpright (N= 1556) Lying down (N= 1537)
Birth-related, n (%)
Cord blood sampling 1025 (66.21) 940 (61.56) 1.012 (1.010 to 1.013)*
Missing 8 10
Resuscitation 206 (13.24) 180 (11.71) 1.32 (0.89 to 1.44)
Facial oxygen 122 (7.85) 94 (6.12)
Suction 75 (4.83) 74 (4.82)
Bag and mask ventilation 82 (5.28) 82 (5.34)
Intubation 6 (0.39) 8 (0.52)
Complex resuscitation 4 (0.26) 1 (0.07)
Missing 2 2
HLC admissions
Level of care (in days), mean (SD)
Special care 0.10 (0.65) 0.14 (1.16) –0.042 (–0.127 to 0.046)
Missing 13 7
High dependency 0.02 (0.17) 0.03 (0.33) –0.010 (–0.035 to 0.015)
Missing 9 4
Intensive care 0.04 (0.83) 0.03 (0.32) 0.017 (–0.041 to 0.076)
Missing 9 3
Surgery performed, n (%) 2 (0.13) 3 (0.20)
Missing 9 4
Transfer to another hospital, n (%) 2 (0.13) 4 (0.26)
Missing 9 3
Neonatal death, n (%) 0 0
Missing 33 29
Investigations, mean (SD)
Radiography 0.02 (0.21) 0.04 (0.49) –0.015 (–0.050 to 0.197)
Missing 11 7
CT 0 (0) 0.002 (0.447) –0.002 (–0.005 to 0.001)
Missing 10 6
MRI 0.0020 (0.0440) 0.0007 (0.0256) 0.0013 (–0.002 to 0.005)
Missing 10 6
Hospital length of stay, mean (SD)
Length of stay (days) 3 (1.93) 3.07 (3.15) –0.067 (–0.308 to 0.174)
Missing 6 5
*p< 0.01.
CT, computerised tomography; MD, mean difference; MRI, magnetic resonance imaging.
a Adjusted for centre.
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TABLE 21 Breakdown of health-care resource use at 1 year over the last 12 months for mothers and their infants
Resource use category
Trial arm
MD (99% CI)a
Upright (N= 1556) Lying down (N= 1537)
n Missing Min. Max. Mean (SD) n Missing Min. Max. Mean (SD)
Maternal
Outpatient visits
Perineal care clinic 941 615 0 10 0.140 (0.781) 936 601 0 10 0.109 (0.711) 0.030 (–0.059 to 0.118)
Gynaecological 925 631 0 8 0.144 (0.590) 931 606 0 10 0.179 (0.815) –0.035 (–0.120 to 0.050)
Surgical 944 612 0 6 0.035 (0.322) 936 601 0 5 0.049 (0.346) –0.014 (–0.054 to 0.025)
Other 927 629 0 50 0.514 (2.371) 920 617 0 35 0.414 (1.814) 0.099 (–0.154 to 0.715)
Hospital visits
Hospital inpatient (days) 935 621 0 28 0.198 (1.328) 927 610 0 24 0.201 (1.257) –0.003 (–0.120 to 0.115)
Number of operations 950 606 0 2 0.036 (0.202) 942 595 0 2 0.050 (0.232) –0.014 (–0.040 to 0.012)
Infant
Outpatient visits
Orthopaedic 943 613 0 20 0.060 (0.760) 935 602 0 10 0.056 (0.466) 0.005 (–0.070 to 0.080)
Paediatric 923 633 0 8 0.250 (0.745) 912 625 0 20 0.279 (1.077) –0.027 (–0.138 to 0.084)
Hearing 942 614 0 4 0.037 (0.272) 937 600 0 10 0.043 (0.411) –0.006 (–0.047 to 0.036)
Eye 935 621 0 3 0.042 (0.248) 932 605 0 3 0.062 (0.305) –0.021 (–0.054 to 0.013)
Dermatology 944 612 0 6 0.039 (0.328) 938 599 0 5 0.036 (0.282) 0.003 (–0.033 to 0.039)
Other 930 626 0 10 0.206 (0.855) 924 613 0 22 0.297 (1.378) –0.090 (–0.225 to 0.048)
Hospital visits
Hospital inpatient (days) 928 628 0 21 0.374 (1.441) 919 618 0 45 0.491 (2.245) –0.123 (–0.344 to 0.103)
Number of operations 950 606 0 2 0.015 (0.129) 942 595 0 1 0.023 (0.151) –0.009 (–0.025 to 0.008)
Max., maximum; MD, mean difference; min., minimum.
a Adjusted for centre.
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NHS costs
Patterns of missing data for summary cost categories using a complete-case analysis are presented in
Figures 11 and 12. It was evident from the plots that in each trial arm the number of missing data from
trial entry to hospital discharge was low following a primarily monotonic missing data pattern. A larger
number of missing data out of the overall data available was observed at the 12-month follow-up. The
charts showed the potential cost information available (indicated by the grey area) to inform the multiple
imputation model. The frequency of missing information in each trial arm and for all categories of health-
care resource use are reported in Tables 19–21.
TABLE 22 Maternal and infant health-care resource use for HLC admissions from trial entry to hospital discharge
for women consuming the resource use category
Health-care resource
use
Trial arm
Upright Lying down
n Mean (SD) Min. Max.
Width
of IQR n Mean (SD) Min. Max.
Width
of IQR
Mothers admitted to HLC
Level of care (days)
Level 0 28 1.928 (1.676) 1 8 1 17 2.235 (2.137) 1 8 2
Level 1 56 1.125 (0.384) 1 3 0 38 1.184 (0.512) 1 3 0
Level 2 23 1.391 (0.941) 1 4 0 26 1.346 (0.629) 1 3 1
Level 3 6 1.667 (0.408) 1 2 0 2 1 (0) 1 1 0
Surgery performed 7 – – – – 4 – – – –
Transfer to another
hospital
2 – – – – 0 – – – –
Investigations
Radiography 4 1.2 (0.5) 1 2 1 5 1.2 (0.447) 1 2 1
CT 2 1 (0) 1 1 0 1 1 1 1 0
MRI – – – – – 1 1 1 1 0
Infants admitted to HLC
Level of care (days)
Special care 58 2.66 (2.15) 1 11 3 53 4.08 (4.78) 1 30 13
High dependency 15 1.53 (0.92) 1 3 2 14 2.71 (2.27) 1 9 8
Intensive care 17 3.88 (7.16) 1 31 2 14 2.79 (1.89) 1 7 6
Surgery performed 2 – – – – 3 – – – –
Transfer to another
hospital
4 – – – – 2 – – – –
Neonatal death 0 – – – – 0 – – – –
Investigations
Radiography 26 1.35 (0.85) 1 5 0 21 2.76 (3.27) 1 13 9
CT – – – – – 3 1 (0) 1 1 0
MRI 3 1 (0) 1 1 0 1 1 1 1 0
CT, computerised tomography; IQR, interquartile range; max., maximum; min., minimum; MRI, magnetic resonance imaging.
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Table 24 reports the results of the cost analysis using multiple imputation over the study period for mothers
and their babies. A statistically significant mean cost difference (95% CI) of £59 (£6 to £111) between trial
arms favouring the lying-down policy was detected in the delivery-related cost category. This translated into a
statistically significant mean difference (95% CI) of £78 (£13 to £143) from trial entry to hospital discharge
per delivery favouring the lying-down strategy. A significant mean cost difference (95% CI) of £0.002 (£0.001
to £0.004) favouring the lying-down position was observed for the birth-related cost category. This difference
disappeared when adding the cost of HLC admissions to the total cost for infants from trial entry to hospital
discharge. A summary of the overall costs from trial entry to 12-month follow-up for women and their infants
using multiple imputation is also shown at the end of Table 24. The mean (SE) total cost per woman/infant
pair at 12-month follow-up (adding all categories of costs) was estimated to be £3207 (£73) and £3252 (£81)
in the upright and lying-down positions, respectively, a non-significant mean cost difference (95% CI) of –£42
(–£254 to £169) favouring the upright position.
TABLE 23 Breakdown of health-care resource use at 1 year over the last 12 months for mothers and their infants
consuming the resource use category
Health-care resource use
Trial arm
Upright Lying down
n Min. Max.
Width
of IQR Mean (SD) n Min. Max.
Width
of IQR Mean (SD)
Maternal
Outpatient visits
Perineal care clinic 55 1 10 2 2.4 (2.257) 38 1 10 2 2.684 (2.384)
Gynaecological 75 1 8 1 1.773 (1.192) 80 1 10 1 2.088 (1.943)
Surgical 16 1 6 2 2.063 (1.436) 26 1 5 1 1.770 (1.142)
Other 135 1 50 3 3.526 (5.303) 113 1 35 2 3.372 (4.117)
Hospital visits
Hospital inpatient (days) 49 1 28 2 3.776 (4.534) 48 1 24 4 3.875 (4.072)
Number of operations 31 1 2 0 1.097 (0.301) 44 1 2 0 1.068 (0.255)
Infant
Outpatient visits
Orthopaedic 21 1 20 1 2.714 (4.429) 24 1 10 24 2.167 (2.014)
Paediatric 130 1 8 1 1.777 (1.109) 118 1 20 1 2.153 (2.229)
Hearing 23 1 4 0 1.522 (0.898) 23 1 10 14 1.739 (2.027)
Eye 30 1 3 1 1.3 (0.535) 43 1 3 1 1.349 (0.529)
Dermatology 19 1 6 1 1.947 (1.311) 21 1 5 1 1.619 (1.024)
Other 84 1 10 2 2.286 (1.834) 87 1 22 3 3.149 (3.360)
Hospital visits
Hospital inpatient (days) 102 1 21 4 3.402 (2.943) 113 1 45 4 3.991 (5.218)
Number of operations 13 1 2 0 1.077 (0.277) 22 1 1 0 1 (0)
IQR, interquartile range; max., maximum; min., minimum.
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Delivery related (mother)
HLC admission (mother)
Up to discharge (mother)
Birth related (baby)
HLC admission costs (baby)
Up to discharge (baby)
Up to discharge (mother/baby)
Maternal costs at 12 months
Infant costs at 12 months
Follow-up costs at 12 months
Total costs (mother/baby pair)
1556 individuals
Observed
Missing
FIGURE 11 Pattern of missing data for main categories of costs for the upright group. Blue shading represents
missing data for one or more individuals (horizontal axis) for a particular cost variable (vertical axis); green shading
represents observed data.
Delivery related (mother)
HLC admission (mother)
Up to discharge (mother)
Birth related (baby)
HLC admission costs (baby)
Up to discharge (baby)
Up to discharge (mother/baby)
Maternal costs at 12 months
Infant costs at 12 months
Follow-up costs at 12 months
Total costs (mother/baby pair)
1537 individuals
Observed
Missing
FIGURE 12 Pattern of missing data for main categories of costs for the lying-down group. Blue shading represents
missing data for one or more individuals (horizontal axis) for a particular cost variable (vertical axis); green shading
represents observed data.
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Maternal health-related quality of life at 12-month follow-up
Summary EQ-5D-3L and SF-6D scores at 12-month follow-up for each trial arm using a multiple imputation
analysis is reported in Table 25. Quality-of-life scores were very similar (almost identical) between trial arms
for both instruments and therefore no significant mean differences were detected.
TABLE 24 Cost analysis (2013/14 UK £) of maternal health-care resource use over the study period using
multiple imputation
Cost category
Trial arm
MD (95% CI)a
Upright (N= 1556) Lying down (N= 1537)
Mean (SE) Mean (SE)
Maternal
From trial entry discharge
Total delivery related 2283 (19) 2225 (19) 59 (6 to 111)*
Total cost HLC admissions 92 (12) 73 (11) 20 (–11 to 51)
Total cost per delivery 2375 (24) 2298 (23) 78 (13 to 143)*
Follow-up costs
Total outpatient visits 104 (11) 94 (9) 10 (–17 to 37)
Hospital admissions 159 (35) 159 (30) 0.09 (–96 to 97)
Total cost per delivery 263 (37) 252 (33) 13 (–84 to 109)
Infant
From trial entry to discharge
Total birth related 0.033 (0.001) 0.031 (0.001) 0.002 (0.001 to 0.004)*
Total cost HLC admissions 108 (28) 114 (22) –6 (–76 to 64)
Total cost per baby 108 (28) 114 (22) –6 (76 to 63)
Follow-up costs
Total outpatient visits 129 (9) 153 (13) –23 (–54 to 8)
Hospital admissions 333 (0) 434 (56) –102 (–238 to 34)
Total cost per baby 462 (42) 587 (68) –123 (–273 to 34)
Total 12-month follow-up costs 725 (58) 839 (71) –113 (–293 to 66)
Total costs per woman/baby pair 3207 (73) 3252 (81) –42 (–254) to 169)
*p < 0.05.
MD, mean difference.
a Adjusted for centre.
TABLE 25 Maternal HRQoL using EQ-5D-3L and SF-6D scores at 12-month follow-up using multiple imputation
HRQoL instrument n Mean SE n Mean SE MD (95% CI)a
EQ-5D-3L score 1556 0.919 0.005 1537 0.922 0.004 –0.003 (–0.016 to 0.011)
SF-6D score 1556 0.802 0.004 1537 0.805 0.004 –0.004 (–0.015 to 0.006)
MD, mean difference.
a Adjusted for centre.
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The distribution of responses of available data for both instruments is reported in detail in Tables 26 and 27,
respectively. It is clear that, using both instruments, the majority of women participating in BUMPES
reported a good quality of life at 1 year post delivery.
Cost-effectiveness analysis as a secondary outcome in the
economic evaluation
A summary of cost-effectiveness results comparing upright with lying-down positions during the second
stage of labour is shown in Table 28. The ICER (95% CI) was estimated to be £722 (–£2968 to £6358) per
additional case of SVB.
TABLE 26 Distribution of EQ-5D-3L responses across the dimensions for available data at 12-month follow-up
EQ-5D-3L dimension
Trial arm
Upright (N= 1556), n (%) Lying down (N= 1537), n (%)
Mobility
No problems 809 (94.5) 811 (95.6)
Some problems 46 (5.4) 37 (4.4)
Confined to bed 1 (0.1) 0 (0.0)
Missing 700 689
Self-care
No problems 850 (99.1) 845 (99.7)
Some problems 6 (0.7) 3 (0.4)
Unable to wash or dress 1 (0.1) 0 (0.0)
Missing 699 689
Usual activities
No problems 798 (93.3) 787 (92.7)
Some problems 56 (6.6) 61 (7.2)
Unable to perform activities 1 (0.1) 1 (0.1)
Missing 701 688
Pain/discomfort
No pain 687 (80.4) 669 (79.1)
Moderate pain 161 (18.9) 171 (20.2)
Extreme pain 6 (0.7) 6 (0.7)
Missing 702 691
Anxiety/depression
Not anxious or depressed 702 (82.0) 708 (83.5)
Moderately anxious or depressed 140 (16.4) 133 (15.7)
Extremely anxious or depressed 14 (1.6) 7 (0.8)
Missing 700 689
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TABLE 27 Distribution of SF-12 responses across the dimensions for available data at 12-month follow-up
SF-12 dimension
Trial arm
Upright (N= 1556), n (%) Lying down (N= 1537), n (%)
General health
Excellent 172 (18.2) 168 (17.9)
Very good 465 (49.2) 473 (50.5)
Good 261 (27.6) 259 (27.6)
Fair 38 (4.0) 36 (3.8)
Poor 10 (1.1) 1 (0.1)
Missing 610 600
Moderate activities
Yes, limited a lot 24 (2.5) 21 (2.2)
Yes, limited a little 76 (8.0) 79 (8.4)
No, not limited at all 848 (89.5) 837 (89.3)
Missing 608 600
Climbing several flights of stairs
Yes, limited a lot 28 (3.0) 24 (2.6)
Yes, limited a little 119 (12.7) 120 (13.0)
No, not limited at all 792 (84.4) 782 (84.5)
Missing 617 611
Accomplished less than would like (physical health)
All of the time 10 (1.1) 4 (0.4)
Most of the time 28 (3.0) 25 (2.7)
Some of the time 64 (6.8) 69 (7.4)
A little of the time 152 (16.1) 146 (15.6)
None of the time 690 (73.1) 693 (74.0)
Missing 612 600
Limited in the kind of work/activities (physical health)
All of the time 8 (0.9) 5 (0.5)
Most of the time 20 (2.1) 12 (1.3)
Some of the time 44 (4.7) 52 (5.6)
A little of the time 130 (13.8) 109 (11.7)
None of the time 741 (78.6) 754 (80.9)
Missing 613 605
Accomplished less than would like (emotional health)
All of the time 8 (0.9) 2 (0.2)
Most of the time 26 (2.8) 21 (2.2)
Some of the time 88 (9.3) 79 (8.4)
A little of the time 184 (19.5) 179 (19.1)
None of the time 638 (67.6) 658 (70.1)
Missing 612 598
continued
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TABLE 27 Distribution of SF-12 responses across the dimensions for available data at 12-month follow-up (continued )
SF-12 dimension
Trial arm
Upright (N= 1556), n (%) Lying down (N= 1537), n (%)
Less careful than usual (emotional health)
All of the time 6 (0.6) 2 (0.2)
Most of the time 17 (1.8) 15 (1.6)
Some of the time 70 (7.4) 56 (6.0)
A little of the time 153 (16.3) 152 (16.3)
None of the time 695 (73.9) 709 (75.9)
Missing 615 603
Pain interfering with normal work
Not at all 719 (76.2) 706 (75.1)
A little bit 165 (17.5) 186 (19.8)
Moderately 35 (3.7) 26 (2.8)
Quite a bit 21 (2.2) 18 (1.9)
Extremely 4 (0.4) 4 (0.4)
Missing 612 597
Felt calm and peaceful
All of the time 81 (8.6) 87 (9.3)
Most of the time 510 (54.0) 490 (52.1)
Some of the time 240 (25.4) 244 (26.0)
A little of the time 86 (9.1) 103 (11.0)
None of the time 27 (2.9) 16 (1.7)
Missing 612 597
Have a lot of energy
All of the time 47 (5.0) 46 (4.9)
Most of the time 432 (45.7) 440 (46.9)
Some of the time 310 (32.8) 302 (32.2)
A little of the time 109 (11.5) 115 (12.3)
None of the time 47 (5.0) 35 (3.7)
Missing 611 599
Felt downhearted and low
All of the time 10 (1.1) 9 (1.0)
Most of the time 35 (3.7) 36 (3.8)
Some of the time 174 (18.5) 180 (19.2)
A little of the time 346 (36.8) 341 (36.4)
None of the time 376 (40.0) 372 (39.7)
Missing 615 599
Physical/emotional health interfered with social activities
All of the time 7 (0.7) 5 (0.5)
Most of the time 26 (2.8) 21 (2.2)
Some of the time 105 (11.1) 102 (10.9)
A little of the time 173 (18.3) 186 (19.9)
None of the time 636 (67.2) 623 (66.5)
Missing 609 600
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Discussion
This chapter has described in detail the methods and results of the economic evaluation conducted as part
of the BUMPES trial. We have implemented a robust methodology based on more recent guidance to
present these results.58
Our results suggested that women randomised to the lying-down position consumed significantly fewer
resources than those randomised to an upright policy during the original hospital stay. Such results were
driven by more SVBs in the lying-down treatment arm. Infants incurred similar costs in both arms of the trial
during this time. At the 12-month follow-up, no significant overall cost differences were observed between
upright and lying-down positions for mothers or their babies. The significantly higher costs incurred from trial
entry to discharge by women in the upright group were offset by the slightly, but non-significantly, higher
costs incurred during follow-up by the babies of women in the lying-down arm. A possible explanation is
that SVB was associated with higher follow-up costs than instrumental delivery or caesarean section.
However, additional analysis assessing follow-up costs by mode of delivery between the trial groups
suggested that this was not the case (data available from the corresponding author). No evidence of
differences was found for the other secondary maternal outcomes, neonatal clinical outcomes or maternal
HRQoL. Therefore, the results of the cost–consequences analysis provided robust evidence clearly in favour
of lying down, at no risk to women or their babies, and at no extra cost to the NHS.
Future studies can use the results of our cost-effectiveness analysis using the cost per additional case of SVB
as an outcome measure as the benchmark for future comparisons in the area. However, we recommend
that such comparisons are used with caution owing to well-known problems of comparability to other
disease areas and ‘double-counting’ when estimating the ICER.59,60
To our knowledge, this is the first study reporting an economic evaluation of upright versus lying-down
positions during the second stage of labour in nulliparous women with an epidural. The most comprehensive
systematic review of economic evaluations of potential interventions during intrapartum care has been
recently updated in a NICE clinical guideline.31 The review aimed to identify all published cost-effectiveness
evaluations in the areas within the remit of the guideline that included the second stage of labour, but no
published economic evaluations were identified. Therefore, the results reported here should be considered
the most up-to-date evidence about the cost-effectiveness of alternative position strategies during the
second stage of labour in women with an epidural.
We were not able to collect HRQoL data at trial entry (or late pregnancy) or in the early postnatal period,
precluding the estimation of QALYs. Therefore, one of the limitations of the current analysis is the limited
comparability of our study with evaluations in other health areas using a cost-per-QALY approach, as
recommended by NICE.58 The use of QALYs has the potential to be a feasible and responsive outcome
measure to evaluate the effectiveness of delivery position interventions during labour. A recent study has
assessed the impact of mode of delivery on maternal HRQoL postnatally, suggesting that caesarean section
is associated with larger quality-of-life decrements, followed by instrumental delivery and then SVB.61
TABLE 28 Summary of cost-effectiveness results comparing upright with lying-down position during the second
stage of labour
Position during
labour
Total cost
(2013/14 UK £)
Incremental
costs
Proportion
of SVBs
Incremental
effect (additional
cases of SVB) ICER
Mean (SE) Mean (SE) Mean (SE) Mean (SE) Mean (95% CI)
Lying down 3252 (81) – 0.411 (0.012) – –
Upright 3207 (73) –42 (108) 0.352 (0.012) –0.06 (0.02) 722 (–2968 to 6358)
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Collecting quality-of-life information during late pregnancy and in the early postnatal period to use in cost-
effectiveness analysis is controversial, because there is limited evidence about the validity of recommended
instruments such as the EQ-5D-3L in this context.62,63 However, it would be possible to estimate QALYs in
the BUMPES study using a modelling exercise that synthesises available quality-of-life information during
late pregnancy and in the early postpartum period from a literature review with the collected EQ-5D-3L
data at 12-month follow-up. Such analysis is of interest to the research team and will be explored in
future research. However, we feel that our cost–consequences analysis provides important evidence that
can be considered by decision-makers in obstetrics when making recommendations about position during
the late stages of labour in women with an epidural.
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Chapter 7 Discussion and conclusion
BUMPES is the largest RCT yet undertaken of different positions in labour and their effects on the modeof birth. There is clear evidence of a benefit of adopting a lying-down position in the second stage of
labour for nulliparous women with epidural analgesia, and there are no apparent disadvantages in relation
to either short- or long-term outcomes for either mother or baby. Thus, a clinical improvement (increase in
SVBs) could be achieved by encouraging nulliparous women with epidural analgesia to adopt a lying-down
position during the second stage of labour. The intervention has no resource implications and has no
additional risk to women or their babies, and thus could be implemented rapidly without additional cost.
Like all pragmatic trials, the study has limitations. The reporting of adherence is complex for this trial.
Various options were considered for recording adherence, but, given the size of the trial, many of these,
such as video recordings of the second stage of labour, were both impractical and intrusive. As midwives
recorded observations of the women and the fetus in utero every 15 minutes during labour, it was felt that
asking the midwife to record position of these epochs would facilitate good data collection. However, it
was also recognised that there were a number of clinical reasons why position could not be maintained as
allocated, for example to facilitate the taking of a fetal blood sample or because the fetal heart could not
be easily monitored using an external monitor. Representing these as non-adherent in the analysis would
have been unhelpful.
With an intervention such as this, masking is impossible, so the results may be influenced by the women’s
and the midwives’ perceptions of the different positions in their ability to achieve a SVB. Given that existing
NICE guidance suggests that women with an epidural should be encouraged to adopt whatever upright
position they find comfortable, we might expect the trial results to suggest an improvement in SVB with
an upright position if midwives’ and women’s behaviour was altered in these positions because of a firm
belief that these were preferable. The finding that the lying-down position increases the chances of
achieving a SVB suggests that this potential bias was either absent or minimal in its impact, or that the
benefit of the lying-down position may be even greater in leading to a SVB.
The original commissioning brief for this trial asked for a measure of maternal satisfaction with the
allocated position during labour. This proved particularly challenging, as there are no validated quantitative
measures of maternal satisfaction specific to the labour and birth episode, and unpicking which aspects of
care could improve an individual woman’s satisfaction with her allocated position is difficult. The measure
that was used was therefore created for this trial and so has limited external validity, even though it has
internal validity.
The incidence of SVB in the trial overall was lower than anticipated when the study was being designed.
The estimate of the risk of SVB was calculated using the COMET, which was published in 2001.5 In the
COMET, there were almost no caesarean sections undertaken during the second stage of labour, reflecting
the change in clinical practice in obstetrics between the late 1990s and now.
We can only speculate about the mechanism by which a lying-down position increases the chance of a
SVB. We have no direct measurements of the density of the epidural block in the two positions nor the
level of the block. It is possible that women in the upright position acquired a more dense block around
the birth canal because of the effect of gravity on the epidural drugs, which could have made expulsive
efforts more difficult; however, the similarity of drug doses used in each group would suggest that this is
unlikely. In women in the upright group, who may have been sitting, the pelvic outlet may have been
restricted by the position on the coccyx or by lower genital tract oedema and venous obstruction causing
swelling of the soft tissues obstructing the pelvic outlet. In addition, it is possible that lying down, by
easing pressure of the fetal head on the pelvis, results in improved uterine blood flow and therefore
improved uterine activity. This would suggest a difference in the risk of operative delivery associated with
failure to progress; however, the distribution of indications for operative delivery appeared to be the same
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in both groups. In addition, there was little difference in the use of oxytocin because of delay in labour
progress after trial entry.
The mechanism by which the lying-down position improves the risk of SVB remains unknown; however,
the results of this trial are clear. Among women with an epidural during their first birth, adopting a
lying-down position in the second stage of labour increases the chance of achieving a SVB. The results
cannot be directly extrapolated to multiparous women with an epidural, or to women who do not have
an epidural, in whom the situation may be very different.
Longer-term outcomes
The response rate to the 1-year follow-up was 61%. Therefore, there is a possibility that the follow-up
results are less than robust because of non-response bias. This poor response, despite many attempts to
improve the rate (described in Chapter 8), is a phenomenon increasingly being seen with contemporary
clinical trials in this area. We provided a variety of options for women to complete their questionnaire:
on paper, via the internet or by telephone. The majority of women still prefer to use paper, but, despite
these various offers, the response rate remained poor. Responders and non-responders exhibited clear
differences in a variety of demographic and clinical factors that were anticipated. Women who responded
were more likely to be older, more likely to be white, less likely to live in a deprived area and less likely to
have achieved a SVB. There were, however, no apparent differences between the two randomised groups
in their response rates or characteristics, suggesting that there were minimal biases in the comparison
between the two groups.
The lack of an impact of the risk of SVB on longer-term outcomes, such as faecal incontinence, is of
interest. The observation that IVD is associated with increased risks of faecal incontinence is robust;
however, in the BUMPES trial the differences between the randomised groups of women in their risk of
SVB and instrumental delivery were relatively small, so, although there are associations between different
modes of birth and long-term outcomes, these are likely to be diluted in a trial in which these differences
in actual mode of birth are relatively modest (only a 6% absolute difference in the risk of SVB). This is
likely to explain the lack of an observed difference in long-term outcomes.
Adherence
Adherence is clearly important when considering an intervention of this nature. The observation that there
was greater adherence in the upright group than in the lying-down group suggests that there may be
even greater benefit from adopting a lying-down position if adherence could be improved. However, the
ability to comply with the allocated intervention may be a function of the intervention itself. For example,
women in the lying-down group may be more difficult to monitor when using an external cardiotocograph
monitor because of the ability to position the monitor accurately to pick up the fetal heart rate. If this is
the case, then non-adherence for clinical reasons is to be expected. It would therefore be difficult to
improve adherence in these women if that meant that they could not be effectively and safely monitored.
Further work needs to be undertaken on the association between adherence and various characteristics of
the nature of the non-adherence, and the risk of the various outcomes, before much more can be said
about whether or not improved adherence may improve the benefit of the lying-down position.
Challenges with equipoise
Although the trial was initially expected to recruit from five UK centres, the expansion to 41 centres
suggests that the results have good generalisability, in that a large number of centres participated
throughout the country. However, the reason for the expansion in the number of centres was because of
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the concerns expressed by midwives in terms of recruiting to the trial. It was clear that many midwives did
not have equipoise about position in the second stage of labour for women with an epidural, and in all of
the participating centres it was a relatively small number of midwives who recruited the women in those
centres. At no stage in the trial was there any suggestion that women were expressing a preference not to
participate in the trial if they were approached. This effect of midwives having particular views about the
benefits of position may limit the generalisability if midwives are not prepared to accept the evidence
produced by the BUMPES trial. When there are strong views, for example that an upright position is
preferable to a lying-down position, if the results of BUMPES fail to be implemented, then the population
benefit of a lying-down position in these women will be relatively small. By producing results that
contradict current NICE guidance and what is widely accepted, that is, that an upright position improves
the chances of achieving a SVB, these results challenge an orthodoxy that may make their implementation
more challenging. The results of the trial, however, are clear. If women giving birth to their first babies and
their carers are keen to increase the chances of achieving a SVB, then adopting a lying-down position in
the second stage of labour, for as much of that second stage of labour as can be achieved, results in a
modest but real increase in their chances of doing so. There is no evidence to suggest that this improvement
carries a risk either to the women themselves, in relation to perineal trauma, or to their babies, in relation to
newborn compromise. Similarly, there is no evidence of any long-term risks to the health and well-being of
the women or their babies. Given that there was no evidence of increasing resource consumption with the
intervention, the authors believe that it could be straightforward to implement and therefore realise benefits
for a substantial number of women having their first babies throughout the UK and other countries.
Monitoring adherence
Another observation from the conduct of this trial is whether or not a trial management group can
and should monitor adherence. In general, adherence is often monitored by the DMC, which is the only
group that sees any data by allocated intervention. For drug trials, in which monitoring of adherence may be
relatively straightforward, this may not be a problem. But for interventions that are less well circumscribed,
such as that in BUMPES, it is important that people with a good knowledge of the trial and its interventions
are able to monitor adherence to ensure that there is reasonable separation between the arms of the
trial. This can be achieved by the DMC; however, given the complexity of monitoring adherence to this
intervention, particularly with respect to taking account of clinically acceptable reasons for periods of
non-compliance, such as fetal blood sampling, the nature of DMCs (in that they tend to meet annually)
means that the DMC is removed from the conduct of the trial, which may be a disadvantage. In a pragmatic
trial, there is a clear reluctance to impose strict adherence rules, but it is helpful and useful to identify
centres or particular individuals with very poor adherence so that behaviour can be modified. In BUMPES,
with 41 centres, it was possible to monitor adherence by centre and identify at least one outlier centre
that had particularly poor adherence to one of the allocated arms, which was at odds with all the other
participating centres. This difference did not come to light until the trial investigators had received
agreement from the DMC that the trial management group should be able to monitor adherence by
allocated intervention on an ongoing basis. We believe that there is an important lesson to be learnt here
about the nature of monitoring adherence, and agreements should be in place early in the trial on who
should undertake this, what parameters should be monitored and how this should be overseen carefully to
ensure that the degree of monitoring is reasonable, and that monitoring adherence cannot be used by the
trial management group to make any inferences about outcomes.
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Chapter 8 Nested study
This chapter describes a nested study within the BUMPES trial, which has been published.64
Rationale for nested study
The return rate of 1-year follow-up questionnaires for BUMPES was lower than expected and the use of
incentives to evaluate the impact on questionnaire return rate was discussed by the TSC. It was noted by
the TSC that there was a lack of evidence relating to the value of incentives to increase collection of
follow-up data in trials. As the evidence base for incentives included a variety of populations, it could be
that postnatal women respond differently. A proposal for a nested study within a trial (SWAT) was
therefore developed.
Background
Maximising follow-up rates for postal questionnaires for RCTs is an important aspect of a well-designed
and well-conducted study. Loss to follow-up can lead to bias and compromise the internal and external
validity of the results.
Use of incentives to promote questionnaire return in clinical trials has been researched. Existing systematic
reviews suggest that they are effective,65,66 but not all studies have sufficient funds to use them. Promising
an incentive once data are returned can reduce the cost burden of this approach. Brueton et al.66 found
that an offer of a monetary incentive was comparable with the addition of a monetary incentive with the
questionnaire (pooled RR 1.04, 95% CI 0.91 to 1.19). However, it may be possible to provide further
cost-savings if the offer was restricted to the reminder letters only.
We evaluated the effect of promising a monetary incentive at first mail-out versus a promise on reminder
letters only, with the incentive being posted out on receipt of a completed follow-up questionnaire.
Objective
To assess the effectiveness on the return rate of the 1-year follow-up postal questionnaires for BUMPES
of the promise of a monetary incentive made at the point of sending the questionnaire for the first time
compared with a promise made on reminder letters only.
Trial design
Parallel-group RCT nested within BUMPES.
Study setting
All women randomised into the BUMPES study who consented to be contacted at 12 months and who
had not yet been sent their 1-year follow-up questionnaire were included.
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Participant eligibility
Inclusion criteria
l Recruited to BUMPES.
l Consented at recruitment to receive follow-up questionnaire.
l One-year questionnaire not sent.
Exclusion criteria
l Women who had a stillbirth.
l Women whose infant had died.
l Address details unknown.
l Woman and infant not living at the same address.
Interventions
Women were randomly allocated to the following two groups.
1. Incentive cover letter: this contained details of the promise of a monetary incentive when the
questionnaire was first sent. A £10 gift voucher redeemable at high-street shops was sent to the
woman on return of a completed questionnaire. The cover letter included a sentence explaining that
the voucher was to thank participants for their time and effort. All reminder letters included a sentence
about the incentive.
2. Incentive reminder letters: the standard cover letter did not mention any incentive. All subsequent
reminder letters sent if the questionnaire was not returned detailed the promise of an incentive. A £10 gift
voucher redeemable at high-street shops was sent to the woman on return of a completed questionnaire.
For both groups, women were contacted electronically and via text messaging if the contact details had
been collected. The content of the e-mails and texts sent reflected the group to which the woman was
randomised. All women were provided with an option of completing the questionnaire online.
Outcome measure
Primary outcome measure
The primary outcome measure was questionnaire return, defined as receipt of a completed or partially
completed questionnaire at the BUMPES office.
Secondary outcome measures
The following secondary outcomes were analysed:
l the number of questionnaires returned without chasing by the study team
l the total cost of the vouchers sent out by nested study arm.
Data collection
Recording of questionnaire receipt, date received and voucher sent was made using internal trial
administration systems. Postal versus online receipt was also recorded.
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Sample size
The sample size was predetermined by the numbers of questionnaires remaining to be sent at the point of
start of the nested study.
BUMPES started recruiting in October 2010 and finished in January 2014. A total of 3236 women were
randomised. It was estimated that approximately 1150 women remained to be followed up at the start date
of this study (beginning August 2014). Assuming that approximately 15% of these women would be
excluded from receiving the questionnaire due to stillbirth, infant death, or address details unknown or
different from the infant, 980 women would be eligible to be randomised in the nested study (approximately
490 per group).
In order to assess the detectable effect size possible with the given sample size, we estimated the control
group risk based on current literature. Khadjesari et al.67 investigated the use of an offer of an incentive
[a £10 Amazon (Amazon.com, Inc., Bellevue, WA, USA) gift voucher] versus no offer of an incentive on
follow-up rates in an online trial. They found an increase of 9% (95% CI 5% to 12%) when using the
offer of an incentive. Kenyon et al.68 investigated the use of a monetary incentive included in reminder
letters versus no incentive and found an improvement in the response rate between the two groups of
11.7% (95% CI 4.7% to 18.6%).
The follow-up questionnaire return rate for BUMPES up to June 2014 was 59%. Assuming that this could
increase by at least 5% with use of the offer of an incentive either with an incentive cover letter or with an
incentive reminder letter only, a sample size of 980 would be sufficient to demonstrate an increase in
questionnaire return rate of 8% from 64% in the incentive reminder letter group to 72% in the incentive
cover letter group at a two-sided 5% significance level with 80% power. Figure 13 illustrates the proportion
detectable in the incentive cover letter group for control group risk varying between 60% and 70%. The
detectable difference lies between 8% and 8.5% for varying control group estimates.
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FIGURE 13 Proportion in incentive cover letter group by proportion in control group. Significance = 0.05;
power = 0.80; sample size per group= 490.
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Randomisation
Allocation was by computerised random number generation stratified by BUMPES allocation and by
centre. Randomisation to incentive cover letter or incentive reminder letter occurred at each woman’s
next follow-up point during the conduct of the BUMPES study, with a block size of four. Each BUMPES
participant was randomised to incentive cover letter or incentive reminder letter once only.
Blinding
Trial staff were aware of allocation as a result of the nature of the interventions and the practicalities
involved in sending the letters and the vouchers.
Statistical analysis
For all analyses, participants were analysed in the groups into which they were randomly allocated, that is,
comparing outcomes for women allocated to the incentive cover letter with outcomes for women
allocated to the incentive reminder letter, regardless of allocation received.
All analyses were based on all women randomised for whom data were available.
The flow of participants through the trial was summarised using a CONSORT flow diagram (see Figure 14).
Specifically, the number of women recruited to the BUMPES main trial and subsequently recruited to the
BUMPES SWAT is reported along with reasons for not being included in the SWAT.
Participants in the two randomised groups are described separately with respect to baseline demographics
and clinical characteristics, including the primary outcome for the main BUMPES study, and recorded on
the BUMPES DCB.
Numbers (with percentages) for binary and categorical variables and means (and SDs) or medians
(with lower and upper quartiles) for continuous variables are reported.
The return rate and chase rate before the introduction of the randomised interventions (i.e. before the
SWAT started) and at the end of the study (with both SWAT trial arms combined) are presented using
numbers and percentages.
The return rate and chase rate by method of completion (online vs. postal) are described by trial arm using
numbers and percentages.
An adjusted analysis was performed on the two return rate outcomes adjusting for centre (the stratification
factor at randomisation) as a random effect. The analysis was carried out using log-binomial regression
models and results are presented as adjusted RRs with 95% CIs.
To examine whether or not the effect of when vouchers were sent was consistent across specific subgroups
of women, a subgroup analysis by IMD quintile was prespecified. Results are presented as RR plus 95% CI
for each subgroup, by intervention group, with the p-value for the statistical test of interaction.
Stata/SE for Windows (version 13.1) was used for all analyses.
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Results
Randomisation to the incentive nested study started on 31 July 2014 and continued until all questionnaires
and reminders had been sent (last letter sent 6 March 2015). The total number of women in the SWAT
was 1026. Eight women were excluded from the analysis as it was discovered after they had been
randomised to the SWAT that they had changed address (Figure 14).
Balance between the SWAT trial arms in baseline characteristics and centre of recruitment to BUMPES
was good. There were only small imbalances in onset of labour (spontaneous or induced), diagnosis of
pre-eclampsia and SVB (the BUMPES primary outcome) (Table 29).
The percentage of questionnaires returned before the SWAT started was considerably lower than the
overall percentage returned from participants included in the SWAT (55.6% vs. 73.0%, respectively).
This trend is also seen in the percentage returned without any reminder letters being sent [35.3% vs.
46.8%, respectively (Table 30)].
Return rates by postal and online completion between the two SWAT arms are presented in Table 31.
A total of 152 questionnaires (20.5% of all questionnaires returned) were completed online, with slightly
more being returned online in the reminder letter group than in the cover letter group (18.0% vs. 23.0%).
Figure 15 and Table 32 present the percentages of questionnaires returned, according to how many times
a reminder letter was sent, and broken down by postal versus online completion. A higher percentage of
questionnaires were returned without chasing after receipt of a cover letter promising an incentive than in
the group receiving a standard cover letter (51.5% vs. 42.1%, respectively). However, if a reminder was
sent, fewer women returned the questionnaire in the group receiving the promise of an incentive in the
Analysed in BUMPES main trial
(n = 3093)
Not recruited to BUMPES SWAT
(n = 2067)
• Questionnaires already sent, n = 1913
• Not contactable, n = 6
• Living at different address to infant, n = 91
• Declined to be followed up, n = 6
• Three-month window expired,a n = 45
• Stillbirth/infant death, n = 2
• Other reason, n = 4
Allocated to incentive reminder letter
(n = 518)
Analysed
(n = 515)
• Ineligible women (not contactable) 
   randomised and excluded from analysis, n = 3
Allocated to incentive cover letter
(n = 508)
Analysed
(n = 503)
• Ineligible women (not contactable) 
   randomised and excluded from analysis, n = 5
Recruited to 
BUMPES SWAT
(n = 1026)
FIGURE 14 Nested study participant flow diagram. a, If not contactable after 15 months since randomisation,
questionnaire was not sent.
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TABLE 29 Characteristics prior to study entry
Characteristic
Letter
Cover (N= 503) Reminder (N= 515)
Centre, n (%)
Birmingham Women’s Hospital 13 (2.6) 16 (3.1)
St Thomas’ Hospital 61 (12.1) 60 (11.7)
Queen Alexandra Hospital, Portsmouth 9 (1.8) 8 (1.6)
University Hospital of Wales 36 (7.2) 36 (7.0)
Royal United Hospitals Bath 27 (5.4) 31 (6.0)
Bradford Royal Infirmary 10 (2.0) 12 (2.3)
Jessop Wing, Sheffield Teaching Hospital 20 (4.0) 20 (3.9)
Princess of Wales Hospital 3 (0.6) 2 (0.4)
Singleton Hospital, Swansea 3 (0.6) 1 (0.2)
Royal Gwent Hospital, Newport 17 (3.4) 14 (2.7)
Gloucestershire Royal Hospital 9 (1.8) 9 (1.8)
Nevill Hall Hospital 4 (0.8) 4 (0.8)
Frimley Park Hospital 25 (5.0) 25 (4.9)
Sunderland Royal Hospital 4 (0.8) 6 (1.2)
Pinderfields Hospital 15 (3.0) 14 (2.7)
Warrington Hospital 8 (1.6) 9 (1.8)
Tameside Hospital 4 (0.8) 5 (1.0)
Medway Maritime Hospital 2 (0.4) 1 (0.2)
South Tyneside District Hospital 1 (0.2) 4 (0.8)
Queen Mary’s Hospital, London 13 (2.6) 13 (2.5)
Queen Charlotte’s and Chelsea Hospital 3 (0.6) 4 (0.8)
Queen Elizabeth Hospital 6 (1.2) 7 (1.4)
Great Western Hospital 12 (2.4) 10 (1.9)
Royal Cornwall Hospital 12 (2.4) 12 (2.3)
Bedford Hospital 9 (1.8) 9 (1.8)
University College Hospital, London 12 (2.4) 12 (2.3)
Royal Sussex County Hospital 7 (1.4) 9 (1.8)
North Manchester General Hospital 14 (2.8) 16 (3.1)
New Cross Hospital, Wolverhampton 8 (1.6) 10 (1.9)
James Paget Hospital 11 (2.2) 10 (1.9)
St George’s Hospital 24 (4.8) 23 (4.5)
Princess Royal University Hospital 2 (0.4) 1 (0.2)
King’s College Hospital, London 36 (7.2) 37 (7.2)
St Mary’s Hospital 1 (0.2) 2 (0.4)
Dorset County Hospital 8 (1.6) 8 (1.6)
Kingston Hospital 38 (7.6) 38 (7.4)
Hillingdon Hospital 6 (1.2) 6 (1.2)
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TABLE 29 Characteristics prior to study entry (continued )
Characteristic
Letter
Cover (N= 503) Reminder (N= 515)
Arrowe Park Hospital 6 (1.2) 6 (1.2)
Lewisham Hospital 1 (0.2) 2 (0.4)
Prince Charles Hospital 3 (0.6) 3 (0.6)
Maternal age (years)
Mean (SD) 28.9 (5.6) 29.3 (5.5)
< 20, n (%) 24 (4.8) 24 (4.7)
20–24, n (%) 93 (18.5) 79 (15.3)
25–29, n (%) 133 (26.4) 148 (28.7)
30–34, n (%) 177 (35.2) 180 (35.0)
35–39, n (%) 66 (13.1) 71 (13.8)
≥ 40, n (%) 10 (2.0) 13 (2.5)
Missing 0 0
Gestational age at entry (weeks)
Mean (SD) 40.4 (1.2) 40.3 (1.2)
37+0 to 39+6, n (%) 150 (29.9) 167 (32.5)
40+0 to 41+6, n (%) 320 (63.8) 315 (61.3)
≥ 42+0, n (%) 32 (6.4) 32 (6.2)
Missing 1 1
IMD: quintile, n (%)
First (least deprived) 64 (15.0) 72 (16.3)
Second 72 (16.9) 63 (14.2)
Third 83 (19.5) 91 (20.5)
Fourth 112 (26.3) 129 (29.1)
Fifth (most deprived) 95 (22.3) 88 (19.9)
Wales – not derived 66 59
Postcode missing 11 13
Ethnic group, n (%)
White 415 (83.7) 434 (85.1)
Indian 20 (4.0) 14 (2.8)
Pakistani 9 (1.8) 7 (1.4)
Bangladeshi 2 (0.4) 1 (0.2)
Black African 14 (2.8) 10 (2.0)
Black Caribbean 7 (0.7) 2 (0.4)
Any other ethnic group 29 (5.9) 42 (8.2)
Not known/missing 7 5
continued
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TABLE 29 Characteristics prior to study entry (continued )
Characteristic
Letter
Cover (N= 503) Reminder (N= 515)
BMI at booking visit (kg/m2)
Mean (SD) 25.2 (5.2) 25.2 (5.3)
Height and/or weight not known 17 11
Woman undergone FGM, n (%) 2 (0.4) 0 (0.0)
Missing 1 1
Onset of labour, n (%)
Spontaneous 309 (61.6) 293 (56.9)
Induced 193 (38.5) 222 (43.1)
Missing 1 0
Duration of first stage (minutes)
Median (IQR) 490 (345–675) 505 (360–720)
Geometric mean 473.8 492.2
Missing 4 6
Diagnosis of pre-eclampsia, n (%) 12 (2.4) 22 (4.3)
Missing 2 1
Continuous electronic fetal monitoring, n (%) 484 (96.4) 492 (95.7)
Missing 1 1
Diagnosis of delay requiring intervention, n (%) 266 (53.1) 272 (52.8)
Missing 2 0
Systemic opioids given prior to epidural, n (%) 142 (28.3) 137 (26.6)
Pethidine 103 (72.5) 97 (70.8)
Diamorphine 38 (26.8) 38 (27.7)
Remifentanil 0 (0.0) 1 (0.7)
Morphine 0 (0.0) 0 (0.0)
Meptid 3 (2.1) 3 (2.2)
Missing 1 0
Epidural technique, n (%)
Epidural 485 (96.6) 496 (96.5)
Combined spinal epidural 17 (3.4) 18 (3.5)
Missing 1 1
Epidural maintained with PCEA/infusion, n (%) 359 (73.1) 369 (73.1)
Missing 12 10
Woman’s pain score for last contraction
Median (IQR) 10 (0–32) 10 (0–30)
Missing 59 55
Able to perform straight leg raise, n (%) 381 (80.4) 408 (82.8)
Missing 29 22
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TABLE 29 Characteristics prior to study entry (continued )
Characteristic
Letter
Cover (N= 503) Reminder (N= 515)
Time from VE diagnosing second stage to study entry (minutes)
Median (IQR) 13 (7–26) 15 (8–26)
Apparently randomised before diagnosis of second stagea 33 19
Time apparently > 180 minutesb 4 2
Missing 1 1
Time from study entry to start of recording positions (minutes)
Median (IQR) 0 (–4 to 5) 1 (–3 to 5)
Time from study entry to recording position of > 15 minutes,a
n (%)
38 (7.7) 44 (8.7)
Time apparently > 15 minutes before study entryb 79 68
Missing 9 7
SVB, n (%) 197 (39.2) 181 (35.2)
Missing 0 0
FGM, female genital mutilation; IQR, interquartile range; VE, vaginal examination.
a Values included.
b Values set to missing.
TABLE 30 Return rates by pre and post SWAT
Return rate, n (%)
SWAT
Pre (N= 2067) Post (N= 1018)
Questionnaire returned 1149 (55.6) 743 (73.0)
Missing 0 0
Questionnaire returned without chasing by study team 729 (35.3) 476 (46.8)
Missing 0 0
TABLE 31 Return rates: mode of completion, by incentive
Return rate, n (%)
Letter
Cover (N= 503) Reminder (N= 515)
Questionnaire returned 373 (74.2) 370 (71.8)
Postal 306 (82.0) 285 (77.0)
Online 67 (18.0) 85 (23.0)
Questionnaire returned without chasing by study team 259 (51.5) 217 (42.1)
Postal 207 (79.9) 161 (72.2)
Online 52 (20.1) 56 (25.8)
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cover letter than those receiving a promise in the reminder letter (11.5% vs. 14.6%, respectively, for the
first reminder, and 8.9% vs. 11.5%, respectively, for the second reminder).
For the primary outcome, the percentage of questionnaires returned overall for those receiving the incentive
cover letter was slightly higher than those receiving the incentive reminder letter (74.2% vs. 71.8%,
respectively), but this was not statistically significant at the 5% level (adjusted RR 1.03, 95% CI 0.96 to 1.11)
suggesting no evidence of an effect resulting from when the incentive is offered (Table 33). However, women
who received a cover letter promising an incentive were more likely to return their questionnaire without a
reminder letter being required than those who received a standard cover letter (adjusted RR 1.22, 95% CI
1.07 to 1.39). The mean difference in the total cost of the vouchers was £4.56 (95% CI £4.02 to £5.11), with
the cost being higher in the group receiving the standard cover letter.
The pre-specified subgroup analysis is presented as a forest plot in Figure 16. There is no evidence of
heterogeneity for IMD subgroups for the primary outcome of overall response rate (p = 0.43).
TABLE 32 Return rates by letter and method of completion
Rate, n (%)
Letter
Cover (N= 503) Reminder (N= 515)
Questionnaire returned without chasing by study team 259 (51.5) 217 (42.1)
Postal 207 (79.9) 161 (74.2)
Online 52 (20.1) 56 (25.8)
Questionnaire returned after first reminder 58 (11.5) 75 (14.6)
Postal 48 (82.8) 55 (73.3)
Online 10 (17.2) 20 (26.7)
Questionnaire returned after second reminder 56 (11.1) 78 (15.2)
Postal 51 (91.1) 69 (88.5)
Online 5 (8.9) 9 (11.5)
Did not return questionnaire 130 (25.8) 145 (28.2)
TABLE 33 Outcomes
Outcome
Letter
Adjusted effect measure
(95% CI)Cover (N= 503) Reminder (N= 515)
Primary outcome
Questionnaire returned, n (%) 373 (74.2) 370 (71.8) RRa 1.03 (0.96 to 1.11)
Missing 0 0
Secondary outcomes
Questionnaire returned without chasing by
study team, n (%)
259 (51.5) 217 (42.1) RRa 1.22 (1.07 to 1.39)
Missing 0 0
Total cost of vouchers (£) 3790 1530
Cost of vouchers,b mean (SD) 7.5 (0.2) 3.0 (0.2) MD 4.56 (4.02 to 5.11)
Missing 0 0
MD, mean difference.
a Adjusted for centre.
b Per participant.
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0.74 0.86 1.00 1.16 1.35
Adjusteda RR
(95% CI)
Interaction
p-valueNumber of events/total number (%)
Cover letter Reminder letter
Favours reminder letter Favours cover letter
IMD: quintile 
First (least deprived) 1.08 (0.91 to 1.28)52/64 (81.3) 55/72 (76.4)
Second 1.12 (0.96 to 1.31)63/72 (87.5) 49/63 (77.8)
Third 0.91 (0.77 to 1.08)61/83 (73.5) 72/91 (79.1)
Fourth 1.11 (0.95 to 1.29)85/112 (75.9) 89/129 (69.0)
Fifth (most deprived) 1.06 (0.85 to 1.32)
0.43
62/95 (65.3) 54/88 (61.4)
FIGURE 16 Subgroup analysis for questionnaires returned.
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Discussion
In this SWAT, there is no evidence to suggest that the offer of a monetary incentive at first mail-out,
compared with only when a reminder letter is sent, makes a substantial difference to the overall return
rate of a 1-year follow-up postal questionnaire. Although slightly more questionnaires were returned in the
group receiving the offer at first mail-out (an absolute difference of 3.4%), the corresponding RR of 1.03
(95% CI 0.96 to 1.11) was not statistically significant at the 5% level.
The return rate for women included in the SWAT compared with that before the SWAT was introduced
showed a marked improvement (absolute difference 17%). Although this is not a randomised comparison,
it is consistent with that found by Kenyon et al.68 in a randomised study investigating the inclusion of a
high-street voucher versus no voucher sent with a reminder letter to parents of 7-year-old children, which
showed an increase in the return rate of 11.7% (95% CI 4.7% to 18.6%). This study is included in a
systematic review that showed that the addition of monetary incentives was more effective than no
incentive at increasing response rates to postal questionnaires (RR 1.18, 95% CI 1.09 to 1.28).66
This SWAT used a £10 high-street gift voucher as a monetary incentive. The mean cost of vouchers per
participant was greater in the group receiving the offer at first mail-out (£7.50 vs. £3.00). Coupled with
the lack of evidence of a difference in the overall return rate, this would indicate that sending the offer of
an incentive with a reminder letter only is a cost-effective approach to improving return rates. However,
there is evidence to suggest that the return rate without requiring reminders is higher in the group for
whom the incentive is offered in the first mail-out (absolute difference 9.4%). The cost of administering
the additional reminder letters was not calculated, but is a serious consideration that would need to be
offset against the expected cost of the vouchers and could depend on the resources available as well as
the sample size of the study.
There are ethical issues to consider with the approach of only sending an offer of an incentive to those
participants who do not return their questionnaire promptly. Consideration should be given to the chance
that participants in a study may communicate with each other, and share their experiences regarding
whether or not they received an incentive.
This is the first known SWAT to investigate the use of incentives for improving questionnaire return rates
in a population of first-time mothers with infants around 1 year old. This study suggests that offering
incentives when a reminder is required could be cost-effective depending on the sample size of the study
and hence the resources required to administer the reminder letters.
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Appendix 2 BUMPES: higher level of care data
collection form – woman (version 2.0)
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Appendix 3 BUMPES: higher level of care data
collection form – infant (version 2.0)
DOI: 10.3310/hta21650 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 65
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Bick et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
119
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
120
DOI: 10.3310/hta21650 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 65
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Bick et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
121
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
122
Appendix 4 BUMPES: ‘your labour and birth
experience’ form (version 6.0)
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Appendix 5 BUMPES: 1-year follow-up
(version 3.0)
Pages of the 1-year follow-up questionnaire that contained copyrighted material have been removed.
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Appendix 6 Membership of the Trial Steering
Committee, Data Monitoring Committee and Clinical
Investigator Group
Clinical Investigator Group
l Professor Debra Bick, Professor of Evidence Based Midwifery Practice, King’s College London.
l Dr Annette Briley, Consultant Midwife, Guy’s and St Thomas’ NHS Foundation Trust (replaced
Geraldine O’Sullivan in 2012).
l Professor Peter Brocklehurst, Professor of Women’s Health at UCL.
l Oya Eddama, Health Economist, National Perinatal Epidemiology Unit, University of Oxford.
l Professor Janesh Gupta, Professor/Honorary Consultant in Obstetrics and Gynaecology, Birmingham
University/Birmingham Women’s Foundation NHS Trust.
l Pollyanna Hardy, Senior Trials Statistician, National Perinatal Epidemiology Unit, University of Oxford.
l Professor Edmund Juszczak, Associate Professor–Director, National Perinatal Epidemiology Unit,
University of Oxford.
l Lynn Lynch, Senior Research Midwife, Cardiff University.
l Professor Christine MacArthur, Professor of Maternal and Child Epidemiology, University of Birmingham.
l Professor Rona McCandlish, Epidemiologist: Maternal Health, National Perinatal Epidemiology Unit,
University of Oxford (until 2012).
l Dr Phillip Moore, Consultant Anaesthetist, University Hospital Birmingham NHS Trust.
l Professor Mary Nolan, Professor of Perinatal Education, University of Worcester.
l Dr Felicity Plaat, Lead Clinician and Consultant Anaesthetist, Queen Charlotte’s and the Hammersmith
Hospital/Senior Lecturer, Imperial College London.
l Dr Dean Regier, Senior Health Economist, National Perinatal Epidemiology Unit, University of Oxford
(until 2012).
l Dr Julia Sanders, Consultant Midwife/Reader in Midwifery, Cardiff University.
l Professor Andrew Shennan, Professor of Obstetrics, King’s College London.
l Dr Geraldine O’Sullivan, Lead Clinician in Obstetric Anaesthesia, Guy’s and St Thomas’ NHS Foundation
Trust (deceased 2012).
l Dr Matt Wilson, Consultant in Obstetric Anaesthesia/Senior Lecturer in Anaesthesia, Sheffield Teaching
Hospital/University of Sheffield.
Trial Steering Committee
Independent members:
l Dr Paul Howell, Consultant Anaesthetist, St Bartholomew’s Hospital
l Professor Dame Tina Lavender, Professor in Midwifery, University of Manchester
l Professor Alan Montgomery (Vice-Chairperson), Professor of Medical Statistics and Clinical Trials,
Nottingham Clinical Trials Unit
l Professor Stephen Palmer, Professor of Health Economics, University of York
l Ms Justine Pepperell (Consumer Representative)
l Professor Steve Robson (Chairperson), Professor of Fetal Medicine, Medical School, University of Newcastle.
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Data Monitoring Committee
Independent members:
l Professor Christine Kettle, Professor of Women’s Health, Academic Unit of Obstetrics and Gynaecology,
University Hospital of North Staffordshire and Staffordshire University
l Mr Stephen Walkinshaw (Vice-Chairperson), Consultant in Maternal and Fetal Medicine, Liverpool
Women’s NHS Foundation Trust
l Dr Steve Yentis (Chairperson), Consultant Anaesthetist, Chelsea and Westminster Hospital
l Dr Pat Yudkin, Emeritus Reader in Medical Statistics, University of Oxford.
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Appendix 7 BUMPES: statistical analysis plan
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Appendix 8 BUMPES: health economics
analysis plan
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Appendix 9 List of hospitals contributing to the
BUMPES study
Centre number Centre name
384 Arrowe Park Hospital
373 Bedford Hospital
203 Birmingham Women’s Hospital
152 Bradford Royal Infirmary
379 Dorset County Hospital Dorchester
356 Frimley Park Hospital
353 Gloucestershire Royal Hospital
365 Great Western Hospital
381 Hillingdon Hospital
369 James Paget University Hospital
112 Jessop Wing, Sheffield
380 King’s College London
382 Kingston Hospital
377 Lewisham Hospital
363 Medway Maritime Hospital
358 Neville Hall Hospital
368 New Cross Hospital
370 North Manchester General Hospital
354 Pinderfields Hospital
378 Prince Charles Hospital
351 Princess of Wales Hospital
367 Princess Royal Hospital
279 Queen Alexandra Hospital, Portsmouth
140 Queen Charlotte’s and Chelsea Hospital
364 Queen Elizabeth Hospital
361 Queen Mary’s Hospital
374 Royal Cornwall Hospital
383 Royal Glamorgan Hospital
352 Royal Gwent Hospital, Newport
366 Royal Sussex County Hospital
350 Royal United Hospital, Bath
362 Singleton Hospital, Swansea
360 South Tyneside District Hospital
376 St George’s Hospital
375 St Mary’s Hospital
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Centre number Centre name
261 St Thomas’ Hospital
227 Sunderland Royal Hospital
359 Tameside Hospital
355 University College Hospital, London
173 University Hospital of Wales
357 Warrington Hospital
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Appendix 10 BUMPES: serious adverse event
form (version 2.0)
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Appendix 11 BUMPES: incentive trial protocol
(version 1.0, 8 July 2009)
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Appendix 12 BUMPES: data collection worksheet
(version 5.0)
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Appendix 13 BUMPES: withdrawal form
(version 4.0)
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